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Two novel 7-substituted 4-aminoalkylated quinolines, Nl,Nl-diethyl-N2-(7-
trifuoromethylthio-4-quinolinyl)-1,2-ethanediamine 11 and Nt, Nl-diethyl-N2-(7-
trifuoromethoxy-4-quinolinyl)-1,2-ethanediamine 12 were synthesized via a versatile 
6-step route and their antiplasmodial activities against the chloroquine sensitive D10 
strain of Plasmodium falciparum have been investigated in vitro. A quantitative 
structure activity analysis of these compounds showed an excellent correlation of log 
ICso, corrected for vacuolar accumulation, with log ~-haematin inhibitory activity 
when compared with known values for other analogues substituted at the 7 -position. 
The correlation showed a law accumulation-normalised ICso for 11, which suggests 
that it is the most potent antimalarial at the site of action of all of the analogues of 
this type. 11 and 12 however had relatively high observed IC 50 values compared to 
the other analogues, which can be attributed to their low pKa1 values and 
subsequent low vacuolar accumulation in the parasite. In addition, the 
benzimidazole nucleus, which has similar dipolar character to 4-aminoquinoline 
nucleus, was investigated as alternative template for potential antimalarials. This 
involved the synthesis of the chloroquine-like analogues 2-(5-chlorobenzoimidazol-
1-yl)-N-(2-diethylaminoethylethanamide 13, N-[2-(5-chlorobenzoimidazol-1-yl)ethyl]-
2-( 4-methylpiperazin-1-yl)ethanamide 14 and N-[2-( 5-chlorobenzoimidazol-1-
yl)ethyl]-N-[2-(4-methylpiperazin-1-yl)ethyl]amine 15. The latter two products were 
prepared by a regioselective route to 5-chlorobenzimidazoles. These compounds 
had poor activity against P. falciparum and none showed ~-haematin inhibitory 
activity although their precursor, 5-chloro-1 H-benzimidazole, had ~-haematin 
inhibitory activity. Their poor activity was ascribed to this lack of ~-haematin 
inhibitory activity as well as their low pKa which would result in poor vacuolar 
accumulation. Finally, the novel side chain N-(2-aminoethyl)-2-(4-methylpiperazin-1-
yl)ethanamide 14b incorporated in 14 was coupled to a 7 -chloroquinoline nucleus in 
order to compare the 4-amino-7-chloroquinoline nucleus directly with the 5-
chlorobenzimidazole nucleus. Thus, the analogous 4-aminoquinoline N-[2-(7-chloro-
4-quinolinyl)ethyl]-2-(4-methylpiperazin-1-yl)ethanamide 16 was synthesized. This 
compound retains anti-plasmodial activity, demonstrating that the lack of activity in 
14 and 15 can be ascribed to the replacement of the quinoline nucleus with the 
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Chapter 1: Introduction 1.1 
1. Introduction 
The aim of this project was to utilize the antiplasmodial structure activity relationships 
of 4-aminoquinolines identified by our laboratory in previous studies [1. 2J in the 
synthesis of novel 4-aminoquinolines. These novel analogues would then contribute 
further to our understanding of the mode of action of these compounds . The project 
also investigated an alternative template to the traditional 4-aminoquinoline nucleus, 
namely 6-chlorobenzimidazole. 
1.1. The current malaria situation 
Currently malaria places at risk at least 3 billion people globally and between 1 million 
and 1.5 million people die from the disease annually. Malaria is endemic in the tropics 
and extends to some part of the subtropics (Figure 1.1). The spread of malaria by 
humans traveling by air is now an important cause of malaria deaths in non-malarial 
areas. Fortunately the vector's flight range outside a viable habitat is a maximum of 2 
miles , not taking prevailing winds into account .[3J 
Figure 1.1. A map showing the countries currently affected by ind igenous malaria .13) 
The African continent accounted for 80% of malaria cases in 1990 with the remainder 
clustered in nine countries namely India, Brazil , Afghanistan , Sri-Lanka, Thailand , 










species causing 120 million new cases annually and virtually all malaria deaths. P 
falciparum has developed drug resistant strains starting in Asia [3j and is now almost 
universal. 
Control and eradication of malaria has three main facets. These are: reducing vector 
mosquito numbers; protection of humans from vector mosquitoes and the treatment of 
malaria infected humans to prevent further transmission. 
1.2. Biology of Plasmodium parasites and Anopheles Mosquitoes 
Malaria is caused by the protozoal parasite Plasmodium spp. The life cycle of the 
Plasmodium genus is divided between a vertebrate host and an insect vector. The 
most common species are P.falciparum, P. vivax, P.ovale and Pmalariae of which 
Pma/ariae is the only species that is not exclusively a parasite of the human. The 
female Anophelene mosquito is always the vector. Out of the 380 species of 










Chapter 1: Introduction 1.3 
MAN 
Imm.", "h'"" @~" "hi"" 
l •• """",,,'(6 ;~~o~~:, 
\fo\¥~ 
Ring farm \J \ ~ Q\ ! Microgcimetacyte 
Penetration of red blood cells ~ 
00 ~ ~ @)----'---t-I 
Merozo~es 91 6Macrogametacyte I 
Merozo~1 
/ 





~ r" ;i'~ Macrogametocyte 
~ / ~~\i Hypnoza~e / ~/J7 
~.' ~~ci o-.~ );m~~~~~;: 
Penetration of parenchymal c~~;;r. -~ +-~ 7 Ookinete 
Sporozottes injected by mosqurta -~ 
I 
Oocyst containing Oocyst on stomach wall 
sparozo~es 
LIFE CYCLE of PLASMODIUM spp. 
Adapted and redrawn from NClJC 
Figure 1.2. The life cycle of Plasmodium spp in the human host (hypnozoites do not occur in P. 
falciparum) [41 
The mosquito injects anticoagulant from its salivary gland to ensure an even flowing 
blood meal from the host. Sporozoites in the salivary gland of the mosquito are then 
injected into the host. The sporozoites migrate to the liver and penetrate hepatocytes 
where during a period of 9-16 days they multiply and then migrate into the bloodstream 
and invade erythrocytes. Inside the erythrocyte the parasite either develops into 
merozoites which further reinfect erythrocytes or it develops into micro- and -
macrogametocytes which have no further activity in the host. The macro- and 










microgametocytes exflagellate and macrogametocytes are fertilized to form ookinetes 
that penetrate the cell wall of the midgut and develop into oocysts. After sporogony of 
the oocyst, many sporozoites are formed. The sporozoites then migrate to the salivary 
gland of the mosquito where they can be injected into a host to complete the life cycle 
of the parasite (fig 1.2).[4] 
1.3. Haem detoxification in P. fa/ciparum, 
All symptoms of malaria are associated with the blood stages of the parasite [5J and 
drugs must act strongly against these stages to be efficacious. During the three blood 
stages (ring, trophozoite and blood schizont) the parasite ingests haemoglobin from the 
host as a food source.[61 Inside the food vacuole (Figure 1.3.), an acidic compartment in 
the parasite, the haemoglobin is digested by the specialized enzymes plasmepsins I, II 
and IV, histo aspartic protease and falcipains I, II and III [7 8] as well as falcilysin. Haem 
is released which is then autoxidised to haematin (aquaferriprotoporphyrin IX, H20-
Fe(III)PPIX), a potential toxin to the parasiteJ9, 10] Solubilised haematin is a cytotoxin 
which shows damaging effects to biological membranes [11J and inhibition of several 
enzymes[12J The haematin is then converted to yield haemozoin/ malaria pigment 
which is an insoluble crystalline material.[5] ~-haematin, the synthetic form of 
haemozoin consists of dimers of ferriprotoporphyrin IX which are reported to be linked 
through reciprocal iron-carboxylate bonds to one of the propionic side chains of each 
porphyrin. These dimers interact in the crystal via H-bonding involving the remaining 
propionic acid groups of each porphyrin.[13] The structure of ~-haematin has been 
shown to be identical to that of haemozoin by x-ray diffraction.[14] It was also suggested 
that an enzyme was required, based on harsh conditions required for ~-haematin 
formation synthetically and the observation that an extract from plasmodial membranes 
apparently catalyzes p-haematin formation, which was thought to be polymeric at the 
time [15J. Pre-formed ~-haematin :16 17] and lipids :17·19J however also have a similar 
function and heating the paraSite extract to boiling point still retains the ~-haematin 
promoting activity, arguing against the presence of an enzyme.[16] Later work 
suggested that histidine rich protein II (HRPII) secreted by Plasmodium, initiates or 
catalyzes haemozoin formation.[20-22] In a study of the kinetics of ~-haematin formation 
in concentrated acetate solutions it was observed that haemozoin formation may be a 
unique biomineralization process which proceeds via a rapid precipitation of 
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This view is further supported by a report that Plasmodial histidine rich protein II acts 
as a biomineralization template for haemozoin .124J More research however is still 
required to clarify the mechanism of haemazoin formation. 125J 
Figure 1.3. P. fa/ciparum trophozoite with a forming food vacuole v. [3[ 
1.4. Quinoline anti-malarials. 
1.4.1. History 
Until now the quinolines (Figure 1.4.) have dominated the therapeutic scene as 
antimalarials . Centuries ago, the native inhabitants of Peru already used the bark of 
Cinchona ledgeriana,126) a local tree which contains the four alkaloids quinine and its 
isomers, quinidine, 9-epiquinine and 9-epiquinidine (collectively known as totaquine)[27j 
Of these four alkaloids only quinine and quinidine have strong antimalarial activity .128, 29J 
These alkaloids only became known to Western medicine in 1640. In 1820 quinine 
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The Germans started to investigate and synthesize synthetic antimalarials during World 
War I after their supply of natural quinine alkaloides were cut off by the allied blockade. 
This led to the first synthetic antimalarials, pamaquine (1932) and quinacrine (1933). 
Then in 1935 a German chemist at Bayer I.G. discovered sontoquine and resochin 
(later known as chloroquine). The Germans abandoned resochin because they 
considered it to be clinically too toxicYO] At the beginning of World War II a stock of 
sontoquine (Fig. 1.4.) fell into US hands. This then started a dynamic search for 
analogous quinoline antimalarials, leading to the rediscovery of chloroquine in 1945 
and subsequently to the synthesis of amodiaquine (1945) and primaquine (1950) (Fig. 
1.4) [31] Chloroquine remained the first line prophylaxis and treatment for malaria for 
almost half a century. A new quinoline methanol antimalarial, mefloquine, was 
introduced clinically in 1984 as a result of ongoing research by the Walter Reed Army 
Institute of Research in the USA (Fig. 1.4). A related acridine, pyronaridine, was 
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1.4.2. Mechanism of action 
Many hypotheses have been proposed over the years to explain the activity of 
chloroquine. These can essentially be divided into two groups: those operating within 
the acidic food vacuole of the parasite and those operating in the parasite cytosol 
outside the food vacuole. 
1.4.2.1. Extravacuolar mechanisms 
1.4.2.1.1. DNA binding/intercalation 
Evidence shows that chloroquine and quinine bind to DNA and that chloroquine 
exhibits antibacterial activity by inhibiting DNA and RNA synthesis.[32] The 
concentration however to accomplish this is 1000 times higher than the ICso of 
chloroquine against P. falciparum. Mefloquine which is also active against the blood 
stage of malaria does not intercalate with DNA~33] 
1.4.2.1.2. Inhibition of protein synthesis 
At 3f.lM concentrations, chloroquine is reported to inhibit protein synthesis in P. 
falciparum. These findings could not be reproduced by other studies [34-36] and 
concentrations in excess of the IC50 of chloroquine were required. 
1.4.2.1.3. Inhibition of polyamine metabolism 
Ornithine decarboxylase activity is reportedly inhibited by chloroquine and mefloquine 
in trophozoite extracts but this does not explain chloroquine's blood stage specificity [33] 
as this enzyme is likely to be active in the liver stage as wellP2] 
1.4.2.2. Intravacuolar mechanism 
The aminoalkyl side chain of chloroquine and analogues give these compounds weak 
base properties. The pKa's of chloroquine are 8.3 and 10.2.[37] The free base present 
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food vacuole. At pH 5.3 in the food vacuole the compound becomes protonated. This 
protonated charged form cannot cross the membrane and it is unable to easily diffuse 
out of the vacuole. This causes pH trapping. These factors cause up to 8000-fold 
concentration of the compound in the vacuole. Additional mechanisms appear to be 
responsible to an even greater extent for the accumulation. 
1.4.2.2.1. Increased pH of food vacuole 
It has been argued that chloroquine and analogues accumulate in the food vacuole due 
to their basic character and alter the pH.f37] However no changes [38] [39] or changes of 
less than 0.25 pH units [40] were observed and these changes are too small to account 
for their activity. [33] 
1.4.2.2.2. Inhibition of vacuolar phosphilipase 
Single membrane endocytic vesicles occur in the food vacuole during treatment with 
chloroquine. This could result from the general breakdown in lysosomal function or the 
inhibition of phospholipase enzymes by chloroquine. Once again this mechanism 
requires high concentration of chloroquine and is not blood stage specific,l33] 
1.4.2.2.3. Inhibition of vacuolar protease 
Aspartic proteases, which degrade haemoglobin, are partially inhibited by chloroquine 
,~41] but only at concentrations higher than that of chloroquine occurring in the 
vacuole[25] 
1.4.2.2.4. Degradation of haem 
In two recent studies it has been suggested that only 30% of haem is converted into 
haemozoin and that chloroquine and related compounds inhibit the degradation of most 
of the haem in the parasite. One study suggests that haem is degraded by glutathione 
and that chloroquine inhibits this process to cause the accumulation of toxic haem.[42] 
The other study suggests that hydrogen peroxide which is a by-product from the 
oxidation of ferroprotoporphyrin IX to ferriprotoporphyrin IX, degrades haem and that 
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spectroscopy, chemical analysis of the iron content of various cellular components and 
electron spectroscopic imaging, our laboratory has shown that most of the iron from 
haemoglobin is converted into haemozoin inside the parasitised erythrocyte [44] which 
suggests that the haem degradation is unlikely to be a significant target of these drugs. 
1.4.2.2.5. Inhibition of haemozoin formation 
It has been shown that chloroquine, amodiaquine and quinine directly inhibit the 
synthetic formation of ~-haematin.[45] This suggests that the activity of these drugs in 
vivo which target the erythrocytic stage of malaria involves the inhibition of haemozoin 
formation as a result of direct interaction with Fe(III)PPIX. This hypothesis has also 
been supported by Darn et a/ f16 , 17] Egan et al. have shown that compounds with a 
poor binding constant to haematin have weak antimalarial activity[46] As further 
evidence another study has shown that the cellular uptake of chloroquine is dependent 
on binding to Fe(III)PPIX and that the addition of specific proteinase inhibitors to stop 
the generation of Fe(III)pPIX, inhibit chloroquine uptake and reduce its activity.[47] This 
supports the mechanism further, in that normally chloroquine would bind to Fe(III)PPIX 
in the food vacuole lowering the concentration of its free form and thereby increasing 
the influx of more chloroquine. 
The above evidence strongly favors this mechanism and forms the basis on which this 
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1.5. Quinoline-Fe(III)PPIX interactions 
Based on the inhibition of haemozoin formation hypothesis, the interaction of quinolines 
with haematin (figure 1.5.) is an important focus point for the development of new 
antimalarials. 
o 0 o 0 
Figure 1.5. Structure of haematin. 
The interaction of quinolines and Fe(III)PPIX has been studied in different solvents.[46, 
48-52] In theory, haematin in solution can exist either as a monomer, f.l-oxo-dimer or an 
aggregate of ~l-oxo-dimers, depending on the concentration, pH and ionic strength.[53] 
Brown et al. made an extensive study on the state of haematin in aqueous solution and 
claimed that it extensively dimerised into an f.l-oxo-dimerf54] 
Studies [46,55] of the chloroquine-haematin interaction performed in the pH range of 5.6 
to 9.0 have shown that the complex is virtually unchanged between pH 5.6 and 7.4. As 
interaction with the deprotonated form of the drug (which would be expected to favour 
any coordination with the iron that may occur) does not increase, it would appear that 
the protonation state of the drug and therefore metal-coordination is not important. The 
ability of chloroquine to form complexes with metal free porphyrins, protoporhyrin IX [56J 
and uroporphyrin I [57J with similar strength to corresponding metal porphyrin complexes 
is further evidence that the complexation does not involve metal-coordination. It is 
strongly suggested that the nature of the drug-Fe(III)PPIX association is based on co-
planar IT-IT interactions between the aromatic ring system of chloroquine and the 
porphyrin.[46.56-58J There are cases such as quinine where additional interactions may 
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porphyrin.[59] It is shown that the chloroquine-haematin complex formation is 
predominantly entropically driven based on thermodynamic parameters obtained while 
quinine-haematin complex formation is enthalpically driven,[46] 
Dorn et a/. have measured association constants in an aqueous environment using 
titration calorimetry where large haematin-drug stoichiometries are observed,[6o] There 
is no evidence that the strength of drug-haematin binding is quantitatively related to 
antiplasmodial activity, [45, 60-62] although erythrocytic stage antimalarial compounds all 
form strong complexes with haematin, 
1.6. Drug resistance mechanisms in P. falciparum 
In this thesis only a short discussion will be made on the drug resistance phenomenon, 
Resistance to chloroquine developed slowly and originated simultaneously in the 
1960's in South East Asia and South America, This resistance then spread to all 
malaria endemic parts of the worldJ63] 
A number of theories exist on the resistance mechanism and they can be divided into 
two topics: (i) the parasite gene responsible for resistance and the protein products 
thereof and (ii) the physiological changes or mechanisms in the parasite associated 
with resistance, 
1.6.1. Gene mutation! changes in expression 
Chloroquine resistance has been mapped to a 36 kb segment of chromosome 7 [64] and 
is related to complex polymorphisms, Candidate genes in this segment, cg1 and cg2, 
have been identified but a recent study has indicated that they are not responsible for 
chloroquine resistance.l65] It was then suggested that a nearby gene is probably 
responsible, accounting for the strong linkage with cg1 and cg2[65] Indeed recent 
evidence shows that chloroquine resistance is a result of a gene. pfcrt, which appears 
to be a transmembrane protein consisting of 424 amino acids located close to the cg1 
and cg2 genes, It is localized in the vacuolar membrane and it may be a transporter or 
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mediator. Mutations observed from respectively the Western and Eastern Hemisphere 
are distinctly different which is in accord with the independent development of 
resistance in South America and South East Asia. 
1.6.2. Physiological changes 
A common feature of chloroquine resistance is that chloroquine resistant parasites 
accumulate less drug than their sensitive counterparts.'66.68] 
Others then argued that chloroquine resistance is the result of an impaired amiloride-
sensitive Na+/H+ exchanger (NHE) pump which inhibits chloroquine uptake into the 
parasite.[69, 7Q] Subsequent studies found no effect of amiloride analogues on 
chloroquine uptake and susceptibility of parasites and also no difference in NHE 
activity between sensitive and resistant strains.[71] The involvement of NHE in active 
transport would appear to have been conclusively discounted. 
Geary et at. argued that reduced chloroquine accumulation in resistant parasites is the 
result of an increased vacuolar pH due to a weakened proton pump?2] Krogstad et at. 
however found no significant differences in vacuolar pH between resistant and 
sensitive parasites.f4°] Bray et at. concluded in their studies on the binding of 
chloroquine to haematin that the chloroquine resistance mechanism probably regulates 
the access to haematin, reducing the apparent binding affinity which can be reversed in 
the presence of verapamil. [47, 73J This is consistent with the resistance hypotheses 
arguing that prevention of chloroquine accumulation at the local site of action is the 
basis of the mechanism. 
A few structural changes to the quinolines have been explored to circumvent 
resistance. Altering the number of carbon atoms between the two nitrogens in the 
lateral side chain of chloroquine has demonstrated that only aminoquinolines with side 
chains distinctly shorter or longer (ethyl, propyl, decyl or dodecyl) are also active 
against chloroquine resistant P. falciparum[74] Vippagunta et at. tested thirteen 
chloroquine analogues and found that the diaminoalkyl side chain is an important 
structural determinant in chloroquine drug resistance.[61] Their study also showed that 
the analogue 1 of chloroquine where the tertiary nitrogen of the side chain was 
replaced with a carbon atom had a 4-fold decrease in activity against the sensitive 
strain and a 1.7 fold increase in activity against the resistant strain, This implies that 










drug resistance. Biot et a/. synthesized and studied the effect of introducing a 
ferrocene group in the side chain of chloroquine analogues. One of these compounds, 
2 was reported to be 22 times more active than chloroquine in vitro against resistant 
strains of P fa/ciparum. [75] Another group synthesized and tested a com plex 3 of gold 
with chloroquine which they reported to be more active against chloroquine resistant 
strains than previously reported metal-chloroquine complexes f761 The evidence above 
establishes that it is possible to produce aminoquinolines active against chloroquine 
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1.7. Structure-activity relationships of the aminoquinolines. 
Studies of structure activity relationships and the quantification thereof plays an 
extremely important role in the approach to the design of novel therapeutic agents with 
a specific application such as activity against the erythrocytic stage of malaria in this 
case. A few comprehensive studies to define the pharmacophore of aminoquinoline 
antimalarials will be discussed here, which form the background for the synthetic 
approach of this thesis. 
The results of most studies are compared with chloroquine. Chloroquine is a 4-
aminoquinoline with an electron withdrawing chlorine in the 7 position. Its structure 
contains three nitrogens of which two are weakly basic: the quinoline nitrogen and the 
tertiary nitrogen in a N, N-diethylamino isopentyl side chain. The two nitrogens of the 
side chain are separated by four carbon atoms. 
In a study [62] focused on circumventing the toxicity of tebuquine (an amodiaquine 











5 position (e,g. 4) to prevent bioactivation to a toxic quinonimine, activities of some of 
the compounds were directly related to their cellular accumulation ratios. A study by 
Hawley et al. [77J also showed that some of these compounds and other quinolines 
which inhibit p-haematin formation indicate a correlation between ICso values for 
inhibition of p-haematin formation and accumulation-normalised ICso values against 
cultured parasites. The evidence above establishes that it is possible to produce 
aminoquinolines active against chloroquine resistant P falciparum by modifying the 
aminoquinoline side chain. 
Bisquinolines have also been the focus of a number of stUdies. These are compounds 
in which two quinoline rings are joined by a linker group. The 4-amino-7-
chlorobisquinolines joined by a linear or cyclic alkane or heteroalkane group attached 
to the 4-amino groups of each of the two quinoline rings have been amongst the 
compounds studied. They showed all the characteristics of the monoquinolines and as 
expected associate with haematin,[60] inhibit p-haematin formation [17, 7B, 79J and show 
strong activity. Bisquinolines based on 4,6- and 4,8-diaminoquinolines show much 
lower activity.IBO] It appears therefore that the activity of most bisquinolines can be 
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A comparison of nineteen aminoquinolines [1, to propose a structure-activity relationship 
for chloroquine (Table 1.1.) showed that 2- and 4-aminoquinolines are unique in their 
strong affinity for Fe(III)PPIX, and attachment of side chains to the amino group or the 
presence of the 7 -chloro group has relatively little influence on the strength of 
quinoline-haematin complex formation. For example compounds 3-4 have roughly 
corresponding association constants with haematin (log K from 4.43 to 5.81), table 1.1. 
It was also shown that the 7-chloro group (6 and 8) is important for inhibition of ~­










on this. Compounds 5 and 7, for example, had no ~-haematin inhibitory activity, table 
1.1. The basic amino group in the side chain also appeared to be important for activity 
as the ICso for compound 6 is approximately two orders of magnitude less than 
compound 8. It is suggested that the basic amino group is responsible for vacuolar 
accumulation of the compound by means of pH trapping. Although this at first seems 
to contradict evidence [47 73] that -90% of observed drug accumulations occurs via 
specific binding to haematin, free drug in the parasite vacuole is in fact a critical 
requirement for this binding. Therefore the accumulation of drug through pH trapping is 
likely to be an essential requirement.[1! 
CI£¢ 
5 6 7 
Compound Log K (40% OMSO, pH BHIA 
7.5, 25°C) 
Chloroquine 5.52 ± 0.03 + 
5 4.49 ± 0.01 
6 4.43 ± 0.01 + 
7 4.75 0.03 
8 5.81 ± 0.01 + 
ICso (010 strain of 
P .falciparum)/nM 
38 ± 14 
>10000 
3800 ± 500 
799 ± 404 
49 ± 14 
Table 1.1. Haematin association constants, p-haematin inhibitory activity (BHIA) and leso compared for 
compounds 5-8 and chloroquine. 
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Amino alkyl side chain - length and shape generally causes only small changes in 
haematin association strength, has no effect on inhibition of ~-haematin formation and 




7 -chloro group required 
for inhibition of p-
haematin formation 
\ferminal amino group required for 
strong activity basic, possibly 
enhances vacuolar drug 
accumulation through pH trapping. 
QUinoline nitrogen - basic, possibly 
enhances vacuolar drug accumulation 
through pH trapping 
Figure 1.6. Proposed SARs in chloroquine based on a study of 19 quinolines f1 ] 
Several studies have investigated the effect of replacing the 7 -chiaro group on the 
quinoline ring with other groups. [2.61,74,81] The strong electron withdrawing bromo, iodo, 
nitro and trifluoromethyl analogues (as characterized by their Hammet constants) 
retained strong activity while the weakly electron withdrawing or electron donating 
fluoro, hydroxyl, amino and methoxy derivatives showed reduced or strongly reduced 
activity, The nitro and bromo analogues of chloroquine showed strong ~-haematin 
inhibitory activity while the 7-amino and 6-chloro analogues were unable to inhibit ~­
haematin formation, The 6-chloro analogue also associated poorly with haematin [61, 81] 
was reported. A modest but significant correlation between IC50 for ~-haematin 
formation inhibition and that for inhibition of parasite growth normalized for ~-haematin 
~-oxo dimer binding affinities.[61] Another recent study [2] with different substituents at 
the 7-position on the quinoline ring showed that the group at the 7-position lowers the 
pKa of both the quinolinium nitrogen and the tertiary amino nitrogen in the side chain of 
chloroquine analogues, The quinolinium nitrogen pKa ranges from 6.28 in the strongly 
electron withdrawing nitro derivative to 8.36 in the electron donating amino derivative. 
For the tertiary amino nitrogen the pKa ranged from 7,65 in the trifuoromethyl derivative 
to 10.02 in the amino derivative. Using these pKa values the accumulation ratios 
(concentration of the compounds inside the food vacuole relative to that outside the 
food vacuole) were estimated using equation 1. This was then compared with 





















Chapter 1: Introduction 1.18 
each derivative with equation 2. This normalised anti plasmodial ICso gave a good 
correlation with BHIAso (activity of compound which would inhibit 50% of ~-haematin 
formation) values for the same derivatives (Figure 1.7.d). Graphs of log ICso against 
log K (Fig. 1.7 .. a), log ICso against log BH1Aso (Fig. 1.7.b) and log (ICsoxa) against log K 
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Figure 1.7. Correlation of log IC50 values against log K (a); log ICso against log BHIAso (b); log ICso, 
corrected for the extent of vacuolar accumulation, against log K (c); log ICsQ, corrected for the extent of 










A further set of formulae (equations 3-7) was proposed in this study ,2] to describe the 
quantitative structure activity relationships of the 4 aminoquinolines and to make 
predictions for new compounds. 
pKa1 = -1.90am + 8.2 (3) 
pKa1 is the acid dissociation constant for quinolinium nitrogen and can be predicted by 
equation 3 using the Hammett meta-substituent constant for the group in the 7 position 
of the quinoline, 
pKa2 = -3.19am +9.5 (4) 
pKa2 is the acid dissociation constant for tertiary amino group in the lateral chain and 
can be predicted by equation 4 using the Hammett meta-substituent constant for the 
group in the 7 position of the quinoline, 
log K = O.29it +4.71 (5) 
The log K value for the 7 -substituted-4-aminoquinoline-haematin association can be 
predicted using equation 5 which incorporates the substituent lipophilicity constant (it), 
log BHIAso = -0.519 x log K-1.06 x am + 3.67 (6) 
The log BHIAso value is predicted using the log K value calculated with equation 5 and 
the Hammett meta-substituent constant for the group in the 7 position of the quinoline, 
log (ICsoxa) = 0.741 x 10gBHIAso -7.97 (7) 
Equation 7 relates the for normalized the ICso value to the BHIAso value. 
Using this set of formulae, the predicted values for the thesis targets, Nl,N2-Diethyl-N2-
(7 -trifuoromethylthio-4-quinolinyl)-1 ,2-ethanediamine 11 and N1, N2-Diethyl-N2-(7-










ChaQ.ter 1.' Introduction 1.20 
Property 11 12 
AR 3110 3271 
a 0.53 0.56 
7.44 7.48 
pKa2 8.22 8.28 
5. 5.01 
log 0.58 0.66 
log (ICsoxa) -7.54 -7.48 
Table 1.2. The predicted values for 11 and 12 calculated using equations 1-7. 
1.8. Alternative structure template for quinoline antimalarials 
Benzimidazoles are known to show a variety of biological activities.[82. 83) The 
mesomeric effect in the imidazole ring system possibly results in a very similar electron 
density profile for the benzimidazole nucleus compared to the 4-aminoquinoline 
nucleus. This makes the benzimidazoles an attractive alternative template for 
investigation as potential antimalarials. 
n = 1.2,3 n = 2,3 
9 10 
Since the 1920's a number of publications reported on benzimidazoles. Synthesis of 2-
~-aminoethylethoxybenzimidazoles were reported in 1929.[84] In 1940 synthesis of 
methoxylated 1-diethylaminoalkylbenzimidazoles was described.18S, 86] In 1944 Clemo 
and Swan also published work on a number of benzimidazoles substituted in position 1 
with the chloroquine side chain[87] Where biological data had been reported it showed 
that none of the above compounds had any activity in avian malaria. Important 
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which forms the bases for our synthetic approach to benzimidazoles as a new structure 
template. Both these groups made benzimidazole analogues (e.g. 9 [88] and 10 [89]) of 
chloroquine which were tested for neuropharmacological action[88. 89] 
1.9. Objectives 
The objectives of this work are the following: 
Synthesis and characterization of two novel 7 -substituted-4-aminoalkylated 
quinolines, N1, N1-diethyl-N2 -(7 -trifuoromethylthio-4-quinolinyl)-1 ,2-ethanediamine 
11 and N1, N1-diethyl-N2-(7 -trifuoromethoxy-4-quinolinyl)-1 ,2-ethanediamine 12 for 
antimalarial activity. 
• Investigation, synthesize and characterization of novel benzimidazole analogues of 
7-substituted-4-aminoalkylated quinolines for antimalarial activity. (13-15) 
• Synthesize and characterization of the corresponding quinoline analogues of the 













d "" 0 ~N" I/"---, CI // N;/ 
16 17 
• The comparison of the biological activity of the structurally analogous 
benzimidazoles and quinolines to determine the effect of the benzimidazole 
nucleus versus the 4-aminoquinoline nucleus. 
• Measurement of pKa values of the basic nitrogens of the targets. 
• Measurement of the log K association constant for each target for association with 
haematin. 
• Measurement of both quantitative ~-haematin inhibitory activity (BHIAso) and 
qualitative ~-Haematin inhibitory activity (BHIA) for each target, in order to 
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2. Synthesis 
2.1. Background 
Chloroquine has been the most widely used anti-malarial agent for almost half a 
century in the prophylaxis and treatment of malaria. The spread of chloroquine 
resistance has virtually voided it of therapeutic value, and this has stimulated great 
interest in the understanding of structure-activity relationships in chloroquine, which 
may contribute to the rational design of superior quinoline antimalarials. 
HN~C 
6 ": ~ ill CI I h- N/.: 2 
8 
chloroquine 
In the introduction, a number of analogues of chloroquine were reviewed where 
either or both the side chain and substituent in the 7 -positions were altered in an 
attempt to improve particular aspects of the antimalarial activity. In this study, four 
aspects in the rational design of novel antimalarials were addressed. 
1. Testing of a hypothesis 
It was firstly decided to test the hypothesis of structure-activity relationships made by 
Kaschula et a/. [90] in which the 7-substituent was varied, and the commercially 
available N,N-diethylethylenediamine side chain was used as the 4-substituent to 
overcome resistance by P. falciparum. The trifluoromethylthio 11 and 
trifluoromethoxy 12 derivatives were selected since they involve a level of electron-
withdrawing character (Figure 2.1.). These substituents are also attractive in the 
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Figure 2.1. 4-aminoquinolines selected to test hypothesis. 
2. A new template 
The benzimidazole nucleus is a possible alternative template for the 4-
aminoquinoline nucleus since from a resonance point of view the benzimidazole 
mimics the dipolar character of the pyridine ring of quinoline (Figure 2.2.). Sterically, 
however, the benzimidazole nucleus is smaller, containing a five-membered ring in 
place of the pyridine ring. As reviewed in chapter 1, benzimidazole was used by 
Knobloch et al. [88J and Heindel et al. [89J to replace the 4-aminoquinoline nucleus in 
chloroquine analogues which were unsuccessful as antimalarial agents.[82J Structure-
activity relationships for these analogues were unresolved and further work was 
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Derivatives 13,14 and 15 were therefore synthesized to explore the structure-activity 
relationships of chloroquine-like benzimidazoles (Figure 2.3.). 
13 14 15 
2.3. benzimidazoles. 
3. Synthesis of a novel side-chain 
N-(2-Aminoethyl)-2-( 4-methylpiperazin-1-yl)ethanamide (Figure 2.4.) 14b was 
designed and synthesized, in a short but difficult synthesis. The primary intention was 
to eventually reduce the secondary amide to a secondary amine to yield a compound 
with a third basic nitrogen capable of increasing vacuolar accumulation of the 5-
chlorobenzimidazoles in the parasite, and also to fine-tune the activity of 7 -chloro-4-
aminoquinoline analogues. 
14b 
Figure 2.4. The side-chain chosen for the regioselective synthesis of 14 and 15. 
4. Benzimidazole nucleus versus the 4-aminoquinoline nucleus. 
In an attempt to establish the efficacy of the benzimidazole nucleus combined with 
the N-(2-Aminoethyl)-2-( 4-methylpiperazin-1-yl)ethanamide side chain, the 7-
chloroquinoline analogue with both this side chain and its reduced form (Figure 2.5.) 












m~ ~N'-. I / /: CI // N 
16 17 
Figure 2.5. Quinoline 'd'U,jU"''' 16 and 17, targeted to compare with benzimidazoles 14 and 15. 
2.2. 7-Substituted-4-N1,N1-diethylethylendiaminequinolines 
2.2.1. Synthesis of 7-X-4-chloroquinolines 
2.2.1.1. Route of Price and Roberts 
The 7-X-4-aminoquinolines, (X = SCF3 , OCF3 ) were synthesized according to 
methodology developed in the synthesis and derivatisation of chloroquine. These 
routes will be briefly discussed, in order to give the background for this method. 
Chloroquine was produced in the United States just after WW II, following the route 
























Scheme 2.1. Commercial route to chloroquine developed by Surrey and Hammer in 1946. Reagents 
and conditions i. CH3COOH (aq), 40-50°C, 15-18 hrs; ii. mineral oil, 250°C, 20 min; iii. 35% NaOH, 
reflux, 2 hrs; iv. mineral oil, 270°C, 5 min; v. POCI3, reflux, 2 hrs: vi. 4-amino-l-diethylaminopentane, 
160-180°C, 7 hrs.!91] 
In the case of chloroquine, m-chloroaniline 18 was condensed with diethyl 2-oxo-
succinate 19 to form enamine 20. Thermal cyclization of 20 gave a 1:1 mixture of 2-
(ethoxycarbonyl)-4-hydroxy-7-chloroquinoline 21a and its 5-chloroisomer 21 b from 
which the desired 21a was isolated by selective crystallization. Hydrolysis to the acid 
followed by decarboxylation and chlorination of the resultant 7 -chloro-4-
hydroxyquinoline 23 gave 4.7-dichloroquinoline 24, which underwent 4-substitution 
with excess 4-amino-1-diethylaminopentane (novol diamine, NDA) for 3-5 hrs at 
160-170°C to yield chloroquine as the free base which was then treated with 
phosphoric acid and isolated as the diphosphate salt. 
Interesting alterations from Surrey and Hammer's laboratory synthesis to plant 
production of chloroquine were reviewed by Kenyon in 1949. One improvement was 
the use of Dowtherm instead of mineral oil for the cyclization and decarboxylation 
steps ii and iv respectively as the mineral oil was difficult to remove owing to its high 
viscosity and tendency to carbonize. The addition of phenol to 24 prior to coupling 
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chloro-4-phenoxyquinoline 25 [92J (Scheme 2.2.) which then couples more readily with 
NDA enabling the use of stoichiometric amounts of NDA and lower reaction 
temperatures. This then eliminated the need to isolate chloroquine as its free base 










Scheme 2.2. Improved preparation of chloroquine from 24. 
Johnson and Buell provided another route, which gave only the desired 7-
chloroisomer upon cyclization. In this route, methyl acrylate and m-chloroaniline 
were condensed to give 26 [93] (Scheme 2.3.). Tosylation and saponification of 26 
gave the acid 27 which was cyclized and detosylated to give 28. Condensation with 
NDA in the presence of an oxidising agent then gave chloroquine. The authors 
claimed that an overall 25% yield from the m-chloroaniline was obtained which 
compares well to the Surrey and Hammer method. 




Scheme 2.3. Synthesis of chloroquine as developed by Johnson and Buell. 193j 
Price and Roberts [941 developed a superior route to 4,7 -dichloroquinoline in 1946 that 
involved condensation of diethyl ethoxymethylenemalonate (EMME) 29 with m-
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predominantly the 7-chloroisomer 31 (80-90%) with only traces of the undesired 5-
chloroisomer. The cyclization and decarboxylation steps ii and iv were both carried 
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Scheme 2.4. Improved route to 4,7 dichloroquinoline [94, Reagents and conditions: i. 100°C, 1 hr; Ii. 
diphenyl ether, reflux, 45 min; iii. 10% NaOH (aq), reflux, 1 hr; iv. 240-270°C; V. POCI3, reflux, 2 hrs. 
The Price and Roberts' method was used to synthesize the 7-X-4-aminoquinolines 
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Scheme 2.6. Route to 7-X-4chloroquinolines, X= SCF3 for 11a-f and 11; OCF3 for 12a-f and 12. 
Reagents and conditions. I. 78°C, 3 hrs; ii. diphenyl ether, reflux, 20-30 minutes; iii. 10% NaOH (aq), 
reflux, 2 hrs; IV. diphenyl ether, reflux, 30 min; v. POCb, 115°, 30 minutes. 
In this dissertation the synthesis started with the appropriate m-substituted aniline 
and EMME 29, which were heated at 10aoe for 3 hrs to afford the acrylates 11 a/12a. 
These were purified by crystallization from ethanol in 93-99% yield. Each purified 
11 a/12a was then refluxed in diphenyl ether for 15-30 minutes to give the desired 7-
sUbstituted quinoline products 11 b/12b regioselectively in 73-75% yields. Because 
of poor solubility characteristics, the regioselectivity was only confirmed by NMR in 
the next step. 
Saponification of 11bf12b by refluxing in 10% l\laOH (aq) for 2 hours gave the 
sodium salts of 11 c/12c which were precipitated out of solution by carefully adjusting 
the pH to neutral with 10% H2S04 to avoid the formation of the water-soluble 
quinolinium ion, The white sludge that formed was filtered off and washed 
extensively with water. The formation of the 7-chloro-regioisomer as 11c/12c in 
stead of the 5-chloro-regioisomer was confirmed by the 1H NMR splitting patterns 
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doublets and H-6 as a doublet of doublets with ortho and meta coupling constants of 
8.4-8.7 and 1.2-1.5 Hz respectively. The analogous 5-regioisomers would have 
revealed a completely different coupling pattern ,[90] since the three aromatic protons 
of the A-ring are next to each other. 
11 c/12c were decarboxylated in refluxing diphenyl ether for 30 minutes to give the 
respective 7-X-4-quinolones 11d/12d in quantitative yields. The 7-X-4-quinolones 
11 d/12d showed the characteristic ortho and meta couplings between the protons of 
the quinoline benzene ring as well as a pair of AB doublets with a coupling constant 
of 4.7 Hz corresponding to H-2 and H-3 in the quinolone pyridine ring (Figure 2.6.), 
thus proving that decarboxylation had taken place. H-2 resonated at a higher 
chemical shift owing to the deshielding effect of the adjacent nitrogen of the [90] 
quinoline pyridine ring. 
HW~ 0 H) I I J '" 47 Hz 
X ~ N H 
I 
H H 
Figure 2.6. Characteristic :H NMR multiplicities and coupling constants for 7-X-4-quinolones 11d/12d. 
Chlorination of 11 d/12d in phosphorus oxychloride and phosphorus pentachloride at 
120°C for 30 minutes gave 7-X-4-chloroquinolines 11e/12e in yields of 88%. Infrared 
spectroscopy revealed the absence of a broad OH band at 3600-3200cm-1. 
It was noted that C-7 in the analogous 7-methoxy derivative studied by Kaschula et 
al. [90] resonated at 161.7 ppm in the DC NMR spectrum, whereas the for X = OCF3 in 
the present case, it appeared at 171.1 ppm. This deshielding downfield shift of 
nearly 10 ppm, going from OCH 3 to OCF3, can be attributed to the inductive effect of 
F3 versus H3• 
The 13C and Infra-red data of compounds 11/12b-d agreed with literature data for 
analogous compounds, and was consistent with these compounds existing 
predominantly in the 4-quinolone tautomeric form (8) rather than as the 4-
hydroxyquinoline tautomer (A), (Scheme 2.5). The prototropic tautomerism of 4-
quinolones, in particular those bearing an ester or carboxyl function at the 3-position 
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to those in this dissertation have been reported by Lubomir et al. [95J to be in the range 
of 172.8-178.4 ppm. Compounds 11/12b-d all had their C-4 chemical shifts in the 
range 176.1-177.8 ppm. The carbonyl Infra-red stretching frequencies for 
compounds 11/12b-d appeared in the range 1640-1620 cm,1 consistent with values 
reported in the literature for 4-quinolinones in the range 1650-1620 cm'1.[9B. 97] 
Furthermore, compounds 11/12b-d showed no hydroxyl stretch at around 3600-3200 
em'1.198J 
Scheme 2.5. Tautomerization of 7-X-4-hydroxyquinoline to 7 -X-4-quinolone. 
FAB High Resolution Mass Spectrometry (HRMS) returned accurate masses to five 
decimal places for all compounds. 
2.2.1.3. 13C_F Coupling 
Carbon signals were assigned by HSQC where possible and by analogy to 
assignments made by Kaschula et a/[2, 90] 
In all13C spectra obtained for 11a-e, 11, 12a-e and 12, a quartet (Figure 2.7.) due to 
C-F coupling was found at 129.3-129.8 ppm and 119.3-123.0 ppm for the SCF3 and 
OCF3 derivatives respectively. This confirmed that fluorine was present as three 
fluorine atoms in accordance with the multiplicity = 2nl + 1 (n = 3, I = 112) = 4 in which 
fluorine has a spin moment of a %. These quartets were spread over ~ 8 ppm, and 
their coupling constants were 308.1-308.6 Hz and 253.4-258.7 Hz for the SCF3 and 
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Figure 2.7 . 13C NMR spectrum of 11 d with an expansion of the quartet observed for SCF3. 
2.2.1.2. Mechanistic comments 
The mechanism for thermal conversion of 11 a/12a to 11 b/12b has not been studied 
in detail before. Kaschula et a/. [90] made the hypothesis that either a polar 
intramolecular nucleophilic substitution mechanism or a 61t-electrocyclic mechanism 
can be considered .[90] 
The nucleophilic substitution mechanism (Scheme 2.7.) involves the attack of the 
aromatic ring on the carbonyl group to produce the polar intermediate (A) in the rate-
determining step. Subsequent expulsion of ethanol followed by rapid tautomerism 
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Scheme 2.7. The proposed cyclization mechanism 1 via a polar intermediate A. 
In contrast, the 61t-electrocyclic mechanism would proceed via the formation of a 
reactive ketene intermediate (C), formed by an entropically driven (favoured by a 
high temperature) expUlsion of ethanol. A subsequent disrotatory 61t-electrocyclic 









Scheme 2.8. The proposed cyclization mechanism 2 via a ketene intermediate C. 
In an attempt to improve the yield of the cyclization reaction, 11 a was refluxed in 
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trifluoride etherate (Table 2.1.). Under these conditions no product formed. The 
normal reaction conditions were also altered by lowering the reaction temperature to 
1 00-i80a C and increasing the reaction times, which also gave poor conversion. The 
lack of any response to the Lewis acid activation, coupled with the high reaction 
temperature necessary for cyclization, appears to favour the proposed entropically-
driven 6n-electrocyclic mechanism. 
Solvent Reagent Temperature Yield 
Dipheny\ ether 100°C 10% 
180°C 
Dichloromethane BF3 . EhO 30°C 0% 
Tetrahydrofurane BF3 . Et20 66°C 0% 
Toluene BF3· Et20 110°C 0% 
ether 260°C 
Table 2.1. Different conditions applied to 11a in an attempt to improve yields. 
2.2.2. Synthesis of the 7 -X-4-aminoquinolines 
The 7-X-4-aminoquinoline analogues were synthesized from their respective 7-X-4-
chloroquinolines 11e/12e by nucleophilic substitution with commercially available 
N,N-diethylethylenediamine via heating together in a sealed thick-walled glass tube 
at 120-150°C for 4-5 hrs. Aqueous 10% NaOH was added to the product and the 
resulting yellow precipitate then extracted into dichloromethane, and the solvent dried 
and removed under reduced pressure. The residue was then chromatographed on 
silica gel using methanol and dichloromethane as eluent to give the free bases of 11, 
12 (Scheme 2.9.). Both compounds showed the expected signals for the 4-
aminoethylated side chain in both the 'H (Figures 2.8. and 2.9.) and 13C NMR spectra 
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Scheme 2.9. Route to 7-X-4-aminoquinolines. Reagents and conditions. i. N,N-diethylethylenediamine, 
120-150°C, 4-5 hrs. 
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Figure 2.9. lH NMR spectrum of 12. The expansion shows the aromatic and NH protons. 
2.3. Aminoamidopiperazinyl side-chain 
As discussed in the introduction of this chapter, part of the development plan was to 
work on both the 7-substituent as well as the 4-side chain. The design of a new side-
chain was multi-faceted , having to take into account the number of nitrogens in the 
chain for improving accumulation as well as synthetic accessibility. In the event, a 
chain was identified incorporating a secondary amide as a connecting group as well 
as a piperazine ring in the view of the latter's well-known activity as a 
pharmacophore. As with chloroquine, a terminal primary amine group was identified 
as providing the connection to the heteroaromatic template. In the case of the 
benzimidazoles , this nitrogen would form part of the imidazole ring _ Synthesis of the 
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2.3.1. Synthesis 
I I 
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14a 14b 
Scheme 2.10. Synthesis route for the_aminoamidopiperazmyl side-chain. Reagents and conditions: i. 
dichloromethane, , Dc -rt, 3 hrs; ii. ethylenediamine, 120°C, 4 hrs. 
N-Methylpiperazine and diisopropylethylamine were added together with 
dichloromethane as solvent and cooled to O°C. Ethyl bromoacetate was slowly 
added over 10 minutes. After 3 hrs the reaction mixture was filtered to remove the 
HOnig's base salt formed. The solvent was removed under reduced pressure and the 
crude product vacuum distilled to yield ester 14a, as a colourless oil with a very low 
viscosity. 
The ester 14a and excess ethylenediamine were stirred at 120"C for 4 hrs, after 
which time TLC (dichloromethane, methanol and ammonia solution, 80:19:1) 
indicated the disappearance of starting material and the formation of a more polar 
product. The excess ethylenediamine was removed under reduced pressure and the 
resulting crude product was vacuum distilled to yield 14b as a viscous yellow oil. 
Carbonization of the crude product at the high temperature made the distillation 
difficult and lowered the overall yield. An aqueous work-up and column 
chromatography of 14a and 14b was avoided because of the high polarity of these 
compounds. Rf values for 14a-b were 0.4 and 0.05 respectively on TLC with 
dichloromethane, methanol and ammonia solution as the mobile phase (80:19:1). 
The 1H NMR spectra for 14a and 14b showed characteristic chemical shifts and 
splitting patterns for the piperazinyl region. The N-CH3 singlet was observed at 2.21-
2.23 ppm in the 1H NMR spectra for 14a and 14b. The piperazinyl protons, assigned 
for positions a and b, were observed as two broad single peaks at 2.40-2.42 and 
2.51-2.55 ppm respectively integrating for two sets of 4 protons. The b-position was 
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confirmed with an HSQC of 14d. The 13C NMR spectrum gave the correct number of 
resonances for 14b (7). 
2.4. Synthesis of 5-chloro-1-aminoalkylated benzimidazoles. 
Two approaches were followed for the synthesis of the 5-chlorobenzimidazoles; 
approach 1, which yielded regioisomers, and approach 2 which was regioselective 
2.4.1. Approach 1. 
The route followed by approach 1 yielded the 5-chloro regioisomer 13 and its 6-
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Scheme 2.11. Regioisomeric route to 5-chlorobenzimidazole 13. Reagents and conditions. i. 
trimethylorthoformate, BF3.Et20, dichloromethane, ooe, 4 hrs; ii. ethyl bromoacetate, sodium hydride, 
tetrahydrofuran, -78°e, 30 minutes; iii. N,N-diethylethylenediamine, 100°, 45 minutes. 
4-chloro-1,2-phenylenediamine was reacted with trimethyl orthoformate in dry 
dichloromethane, and the solution was cooled to aoc before adding boron trifluoride 
etherate. After 4 hrs when TLC indicated complete conversion of starting material, 
the reaction mixture was poured into aqueous Na2C03. The compound was then 
extracted into ethyl acetate followed by dichloromethane, and the organic extracts 
dried. The solvent was removed under reduced pressure and the oily residue 
chromatographed on silica gel using equal parts of petroleum ether and ethyl acetate 










a mixture of ethyl acetate and petroleum ether. The formation of the imidazole ring 
was confirmed by the appearance of a singlet at 8.16 ppm in the 1 H NMR spectrum 
for H-2. The 1H and 13e NMR spectra of revealed two sets of resonances, which 
were tentatively assigned as the two regioisomers 13a and 13a' (scheme 2.11.). 
Interestingly, these appeared not to equilibrate to one thermodynamically more 
favoured form. 
In the next step sodium hydride was added to a cooled solution (O°C) of 13a/13a' in 
dry tetrahydrofuran. For clarity sake, Scheme 2.11. only shows the conversion of 
13a, although in practice both regioisomers were converted. The mixture was stirred 
for 1 hr during which a colour change of orange to green was observed. The mixture 
was then cooled to -78°e and ethyl bromoacetate was slowly added over 10 minutes. 
After 30 minutes the reaction mixture was quenched with saturated ammonium 
chloride solution. The product was then extracted with ethyl acetate and dried. All 
solvent was then removed under reduced pressure and the product recrystallized 
from ethyl acetate to yield 13b/13b' (60%). The 1H NMR spectrum for 13b/13b' 
again showed a double set of signals, indicative once again of the regioisomers. A 
major to minor set of integrals were observed and the major set was picked out and 
assigned for one isomer 13b (arbitrarily assigned). 
The mixture of isomers 13b/13b' was then stirred in N,N-diethylethylenediamine in a 
sealed vessel under N2 at 100ce for 45 minutes. The excess N,N-
diethylethylenediamine was removed under reduced pressure. The resulting oil was 
then column chromatographed on silica gel with a mixture of dichloromethane and 
methanol (80:20) as eluent. This yielded a non-crystalline solid, 13/13' (73%). Once 
again, two sets of signals were observed in the 1 H NrvlR spectra, which further 
supported the presence of regioisomers. Only the set of signals for one of the 
isomers is recorded in the experimental section, and has been arbitrarily associated 
with 13 in the text, although a true assignment of individual isomers was not possible. 
The appearance of a singlet for H-2 at 7.90 ppm for the imidazole ring and the 
resonances for the aliphatic N,N-diethylethylenediamino side chain were noted in the 
1H NMR spectrum. The correct number of 13e NMR resonances (13 for each isomer) 
together with an accurate mass from FAB High Resolution Mass Spectrometry 
(HRMS) was further evidence that structure 13 was obtained in the product mixture. 
At this point it was decided to develop a regioselective route, in view of the difficulty 









2.4.2. Approach 2. 
A regioselective synthetic route was needed to overcome the difficulties associated 
with the regioisomeric route discussed in section 2.4.2. It would entail differentiating 
the two nitrogens of 4-chloro-1,2-phenylenediamine in order to N-substitute the 
nitrogen para to the chlorine. A survey of the literature revealed that in 1969, Heindel 
et al. reported the synthesis of chloroquine-analogous benzimidazoles (Scheme 
2.12.) in which commercially available 2,5-dichloronitrobenzene was used for the 
above mentioned purpose.[8S] The route involved nucleophilic monosubstitution of 
2,5-dichloronitrobenzene at the 2-position followed by nitro group reduction and 
cyclization using EMME. This route yielded only the desired 5-chloroisomer in the 
benzimidazole class. 
(yCI 
c,MNO 33 2 
H-1 L( 
+ H N L-l N~ _____ (YI -...:::::: N r-Tn N-...../ 
2 -l J~~. » ~
CI 1~~ NO, 
II 
H -1 l_ ( 
(YNLTn N-...../ 
M CI NH2 
35 
n = 2,3 
Scheme 2.12. Synthetic route to 37 as reported by Heindel ef a/. [89J Reagents and conditions. i. reflux, 3 
hrs; Ii. stannous chloride, Hel conc., lO°C-rt 2 hrs; iii EMME, 100°C. iv. diphenyl ether, reflux. 20-30 
minutes. 
Heindel's route involved reacting equimolar amounts of the dialkylaminoalkylamine 
and 2,5-dichloronitrobenzene 33 under reflux for 3 hrs in a nucleophilic substitution 
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extracted thoroughly (diethyl ether). The residue from the concentrated ethereal 
phase was either vacuum distilled or recrystallized in the case of solids to yield 34 in 
80-84%. 
The coupled nitro derivative 34 was dissolved in Hel and slowly added to a chilled 
solution of stannous chloride over 5 minutes. The temperature was maintained at 
10°C or lower. This was allowed to stir at room temperature for 2 hrs whereafter it 
was added to chilled aqueous NaOH and extracted into diethyl ether, The dried 
extract was evaporated in vacuo and the resultant oily diamine 35 used directly in the 
cycle-forming reaction. 
The crude amine 35 was heated on a steam cone with EMME until the theoretical 
amount of ethanol had evolved. The oily adduct 36 was then added to refluxing 
diphenyl ether and heated for 20-30 minutes. The diphenyl ether was removed by 
distillation and the benzimidazole 37 was fractionated under vacuum in 52-64% yield 
[89] 
A synthetic variation on the final (cyclization) step in the synthesis of 14 was provided 
by Knobloch et al. [88] (Scheme 2.13). Instead of forming the adduct 36 with EMME 
and performing a thermal cyclization to yield 37, they used the method of Phillips [99] 
in which 38 was dissolved in HCI and added to a diluted solution of methanoic acid. 
The reaction mixture was heated to 120°C for 6 hrs whereafter the product was 
vacuum distilled to yield 39 in 84%. 
~r~ "~N~ 
~NH ~ T~ In-[ M -----lO>-)O ~N~ ~ 
CI NH2 CI~N 
38 no:: 1,2 39 
Scheme 2.13. Implementation of the Phillips' method by Knobloch et al. [881 Reagents and conditions. I. 
methanoic acid, reflux, 6 hours. 
Both these routes were reported to be regioselective and a combination of them were 
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0(CI 
M CI N02 + 
33 
iii 
Scheme 2.14. Synthesis route to 14 and 15. ,C/eagents and conditions. i. dimethylformamide, reflux, 3 
hrs; ii. stannous chloride, Hel conc., OO_rt, 2hrs; iii. methanoic acid, Hel cone., 12QoC, 2.5 hrs; iv. LiAIH4, 
tetrahydrofuran, 70oe, 60 nrs; v. methanoic acid, Hel cone., 120°C, 1 hrs. 
To this end a solution of 14b and 2,5-dichloronitrobenzene in dimethylformamide was 
refluxed for 3 hrs whereafter the reaction mixture was cooled and basified with 10% 
NaOH, The product was then extracted into ethyl acetate. After a charcoal clean, 
the solvent was removed under reduced pressure and the solid recrystallized from 
ethyl acetate and petroleum ether to yield orange crystals of 14c. Its infrared spectra 
showed the presence of a carbonyl group in the 1700 cm-1 region. Its 1H NMR 
spectrum integrated for the correct number of protons and revealed two broad 
singlets at 7.44 ppm for the amide NH and 8.04 ppm for the aromatic NH. The 
correct number of resonances (13) were observed in the DC spectrum. 
14c was dissolved in cone. HCI and added to a chilled solution of stannous chloride 
in conc. HCI. After 2 hrs the reaction mixture was poured into ice and basified by 
adding a stoichiometric amount of NaOH pellets to the solution. The product was 
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solvent was removed under reduced pressure and the resultant solid recrystallized 
from ethyl acetate to yield purple crystals of 14d in a yield of 94%. Three broad 
singlets were now observed for NH protons at 3.45 ppm (NH2)' 3.79 ppm (aromatic 
NH) and at 7.42 (amide NH) at a similar chemical shift to 14c. 
14d was added to a 10% solution of formic acid. The mixture was then acidified with 
conc. HCI and heated to 120°C for 2.5 hrs. On TLC (dichloromethane, methanol 
and ammonia solution, 80:19:1) 14 retained the same Rf value as 14d. After cooling 
to room temperature, the product was extracted into ethyl acetate and dried. All 
solvent was removed by reduced pressure and the target product recrystallized from 
ethyl acetate to yield pink crystals of 14 (87%). Cyclization to the benzimidazole was 
evident from the appearance of a new singlet in both the 1H (7.84 ppm) and proto-
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Figure 2.10. 1 H NMR spectrum of 14. 
It was then decided to reduce the amide in the side chain to introduce another basic 
nitrogen to potentially enhance biological activity. This could only be done by 
reduction of 14d since the benzimidazole C=N double bond is more easily reduced 
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reduce the amide in 14. Although a number of reagents are available for reduction of 
secondary amides to secondary amines, lithium aluminium hydride (LiAIH4) was 
selected for the task. Thus 14d was heated at 70°C with LiAIH4 in dry 
tetrahydrofuran in a thick-walled glass tube with a pressure seal in order to allow 
heating above the boiling point of the solvent (66°C). The mixture was first stirred at 
room temperature for 1 hr and then heated to 70°C for 60 hrs during which it was 
monitored by TLC (dichloromethane, methanol and ammonia solution, 80:19:1) at 
intervals until it appeared that no further reduction was achieved. On cooling, the 
product was slowly quenched with a chilled mixture of tetrahydrofuran, triethylamine 
and water (8:1:1). This mixture was stirred until the colourless aluminium salts had 
formed and then filtered through Celite. The organic solution was dried and removed 
under reduced pressure to yield a mixture of 14d and the reduced amide, 15a 
(scheme 2.14.), as a purple oily residue. Rather than purifying at this stage, 15a was 
subjected to cyclization in view of its high polarity towards column chromatography. 
Thus the crude product was added to a 10% solution of methanoic acid. The mixture 
was then acidified with HCI conc. and heated to 120°C for 1 hr. On cooling, the 
excess water was azeotropically removed with toluene under reduced pressure. The 
crude material was chromatographed with a mixture dichloromethane, methanol and 
ammonia solution (80:19:1) as eluent, to give 15. The 1H NMR spectrum showed the 
presence of four quartets in the region of 2.5-4.5 ppm accounting for the four 
methylene groups in the side chain. The H-2 singlet for the imidazole ring appeared 
slightly more downfield (8.12 ppm). FAB High Resolution Mass Spectrometry 
(HRMS) returned an accurate mass to five decimal places for 15. The polar 
character of 15 prevented successful column chromatographic purification thereof 
and the crude product was submitted for biological assays. 
2.5.7-Chloro-4-aminoamidopiperazinylquinolines 
With the aminoamidopiperazinyl side-chain successfully synthesized and introduced 
into the benzimidazoles, all that remained was to establish the effect of the 
benzimidazole template on biological activity. This was achieved by synthesizing 










benzimidazole target 14, in which only the aromatic nucleus is structurally different to 
14. 
Figure 2.11. The 4-aminoquinoline 16 which is analogues of the benzimidazoles 14, 
The 7-chloro-4-aminoquinoline 16 was synthesized from 4J-dichloroquinoline by 
nucleophilic substitution with the aminoamidopiperazinyl side chain 14b with 
dimethylformamide as solvent in a sealed tube at 120-150°C for 4-5 hrs. The 
reaction was folowed by TLC (dichloromethane, methanol and ammonia solution, 
90:10:0.1) in which 16 had a Rf value of 0.7. For the formation of 16, potassium 
fluoride was added to promote coupling. The reaction mixture was poured into water 
to selectively extract the aminoamidopiperazinyl side chain. The pH was adjusted to 
basic with potassium hydroxide solution and the product extracted with ethyl acetate, 
dried and the solvent removed under reduced pressure. The product was then 
recrystallized to give the free base of 16 (Scheme 2.14.). A characteristic singlet in 
the lH NMR spectrum of 16 for the methylene group a to the amide carbonyl was 
observed at 2.82 ppm as well as a multiplet integrating for the 4 protons of the other 
two aliphatic methylene groups at 3,34 ppm. The 13C NMR spectrum showed a C=O 
carbon resonance downfield at 169.9 ppm. Correct integration of the aliphatic and 
aromatic protons revealed substitution had successfully taken place. 
+ 
24 
Scheme 2,14, Synthesis of the chloroquinoline substituted with aminoamidopiperazinyl side-chain, 
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The attempt at the end of this project to reduce the amido side-chain of 16 with 
lithium aluminium hydride at 70D C in a sealed tube for 3 hours, failed. Mass 
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3. Structure-activity relationsh ips. 
In this chapter the results of the structure-activity relationship (SAR) and quantitative 
structure-activity relationships (QSAR) studies of compounds 9 and 11-16 will be 
discussed. 
3.1. QSAR of short chain 4-aminoquinolines. 
QSAR studies were performed on a number of previously reported short-chain 





X = (a) NH2,(b) OH, (e) OCH" (d) H, (e) CH" (f) F, 
(g)l, (h) Br, (i) CI, Ul CF" (k) N02• (11) SCF" (12) OCF, 
Figure 3.1. The short-chain analogues of chloroquine where group X was vaned.[2] 
3.1.1. Acid dissociation constants 
Results for pKa1 (quinoline ring nitrogen) and pKa2 (tertiary nitrogen of the side-
chain) are shown in table 3.1. 
7-position 
substituent 
pKa1 observed pKaz observed pKal predicted' pKa2 predicted' 
6.56 ± 0.06 8.28 ± 0.05 
6.97±0.1 8.41 ± 0.06 
Table 3.1. Results for pKal and pKa2 compared with predicted values for SCF3 and OCF3 derivatives ( 
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The observed pKa1 values for SCF3 and OCF3 compare poorly with the predicted 
pKa1 values whereas the observed pKa2 values compared very well and in fact are 
identical for the value within experimental error. 
The observed values for the SCh and OCF3 and other short chain analogues [2] 
were plotted against the para- and meta-Hammett (ap and am) constants for the 
group in the 7-position of the quinoline ring respectively (Figure 3.2.). The improved 
p value and a similar r value suggests that using the linear free energy equation with 
the crp constant gives a better predictive equation for the short chain analogues. 
9 9 
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8 Br • 8 F CI CF3 
.- \i .CF1 ~ • (II I (II OH 
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.OCF3 ::s::: 7 0..' T 0.. T • 
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OCF3 • • SCF3 6 6 NO. 
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Hammet constant (0' m) Hammet constant (a p) 
Figure 3.2. (a) Correlation between the quinoline nitrogen pKa (pKa1) and the Hammett constant for the 
meta position (erm) of the group at the 7-position of the quinoline ring in compounds a-k, 11 and 12. 
Without the OH derivative the data conform to the empirical equation pKa1 = -2.13crm + 8.1 (? 0.68, P 
= 0.001). (b) Correlation between the quinoline nitrogen pKa (pKa1) and the Hammett constant for the 
para position (ap) of the group at the 7-position of the quinoline ring. Without the OH derivative the 
correlation improves significantly [21 and the data conform to the empirical equation pKal -1.41crp + 7.7 
(? ::. 0.745, P 00003). (c) Correlation between the pKa of the lateral chain terminal amino group 
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Data conform to tr.e empirical equation pKa2 = -2.06crm +94 = 0.464, P 0600) The N02 derivative 
appears to conform poorly to this correlation as identified in the original study.:2] Its omission leads to a 
significantly better correlation: pKa2 -3:9crm + 9.5 0.697, P 0.0026) Correlation between the 
pKa of the lateral chain terminal amino group (pKa2) and Hammett constant for the para position (crp) of 
the group at the 7-position on the quinoline ring. Data conform to the empirical equation pKa2 =-1 
+ 8.9 (I 0.46, P = 0.021). The N02 derivative appears to conform poorly to thiS correlation. Its 
omission leads to a significantly better correlation: pKa2 = -1.91crp + 8.8 =: 0.6694, P 0.0038). 
In a previous study am was proposed for the calculation of pKa values because the 
correlation was marginally better than that with the ap .[2] As can be seen in figure 
3.2.d, the pKa2 values show a good correlation with G p when SCF3 and OCF3 are 
included. Thus a better correlation is found with G p for both pKa values. 











Figure 3.3. A typical spectrophotometric titration for log K determination (e.g. 11) 
The results for the association constant assay (log K) are shown in table 3.2 (e.g. 11, 
Figure 3.3.). 
X Observed log Predicted log 
4.85 ± 0.03 
4.66 ± 0.06 
Table 3.2. Log K results compared with the predicted values for SCF3 and OCF3 derivatives. log K was 
obtained using a 1: 1 association model derived by Mavuso [100] and values are a mean of three 
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Values for SCF3 and OCF3 were plotted on the same graph as values for derivatives 
a-k (Figure 3.4.). On this graph the SCF3 and OCF3 derivatives lie significantly below 
the line like the CF3 derivative, possibly as suggested previously [2] because of their 
relatively large steric bulk. This would explain the poor agreement of observed log K 
values for SCF3 and OCF3 with predicted values. An almost parallel trend line can be 
fitted to these three points which may indicate a new family of compounds with their 
own linear free energy correlation (dotted line in Fig.3.4.), however owing to the fact 
that there are only three of these derivatives, a statistically significant correlation for 













Lipophilicity constant (n) 
Figure 3.4. Correlation between haematin-aminoquinoline association constant (log K) and the 
lipophilicity constant (it) for the substituent at position-7 on the quinoline ring [2) to which data for the 
SCF3 and OCF3 derivatives have been added. The data for the CI derivative (log K = 5.81) is not shown 
because it lies far above the remaining data. The data for CF3, SCF3 and OCF3 were also not used in 
the correlation. The remaining points conform to the empirical equation log K 0.2901t + 4.71 (r = 0.89, 
P 00001)[2J The CF3, SCF3 and OCF3 derivatives may form their own new linear free energy 
relationship line (. .. "') 
3.1.3. ~-Haematin inhibitory activity (BHIA) 
The qualitative infrared BHIA assay for SCF3 and OCF3 showed inhibitory activity for 
both compounds. The results of a typical infrared assay are shown in figure 3.5. The 
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Figure 3.5. Infra-red spectra of (A) haematin, (B) p-haematin and (C) the product 
formed in the presence of 12 obtained as KBr discs in the region 2000 cm-' -
1000 cm-'. The dotted lines are at 1662 cm" and 1210 cm-'. Absence of a peak at 
1660 cm" in the presence of 12 indicates that it has inhibited p-haematin 
fnrm<'lti()n 
x Observed Predicted' New 
prediction 
2.1 ± 0.2 3.8 5.4 
4.2 ± 0.2 4.6 7.1 
Table 3.3. BHIAso results for SCF3 and OCF3 derivatives compared with predicted values. The 
observed values are a mean of two determinations done in triplicate ± the standard error of the mean. 
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3.6, p-haematin inhibitory activity correlated with both the association constant for haematin-
aminoquinoline association and the vm according to the empirical equation log BHIAso = -(0.519)(109 K) 
1,06vm + 3,67, (I:::: 0,87; and for both of the parameters log K and am pi lies in the range 0,01 -
0,02), SCF3 and OCF3 were not included in the linear relationship 
The obseNed BHIAso (Figure 3.6.) value for the SCF3 derivative compares very 
poorly with the original predicted value (Table 1.2.), while that for the OCF3 is better. 
However, if the obseNed log K values are used to predict the BHIAso values, there is 
a very poor correlation with the predicted values, This suggests that the correlation of 
the quantitative structure-activity relationship used to predict log BHIAso previously 
may indeed be fortuitous as originally suggested (2J or the SCF3 and OCF3 derivatives 
may be outliers and that they interact with haematin in a manner that is structurally 
quite distinct from the remaining compounds. 
3.1.4. Correlation of ICso with BH1Aso and pKa 
The results for the anti plasmodial test of the SCF3 and OCF3 derivatives are shown in 
table 3.4. 
x Observed ICso Observed ICso Predicted ICso 
(010 CO (K1 CO resistant 
sensitive strain) strain) 
94 ± 22 nM 81 ± 5 nM 55 nM 
164 ± 24 nM 103 ± 19 nM 
Table 34. ICso values of SCF3 and OCF3 derivatives against the 01 ° chloroquine sensitive strain and 
K1 chloroquine resistant strain of P fa/ciparum compared with their predicted values, The observed 
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The observed ICso value for SCF3 against the 010 strain falls within one standard 
deviation of the observed ICso against the K1 strain, while for the OCF3 it falls within 
three standard deviations. Thus there is no significant difference in activity against 
the chloroquine sensitive and resistant strains. This finding is probably to be 
expected for these short chain analogues, which have been shown to retain activity 
against chloroquine resistant P. falciparum in a previous study [81] of analogues 
containing other groups at the 7 -position. 
Kaschula et a/. showed an excellent linear correlation between the log of the 
accumulation normalized antiplasmodial activity and the log of the ~-haematin 
inhibitory activity (~ = 0.83, P = 0.0043). SCF3 and OCF3 were plotted on this 
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Figure 3.7. Linear correlation between the log of the normalized antiplasmodial activity and the log of the 
0-haematin inhibitory activity (I =: 0.30, P =: 0.0011 compared to 1 0.33, P = 0.0043 when SCF3 and 
OCF3 are omitted i
21). 
The considerably decreased p value for the linear relationship when SCF3 and OCF3 
are included indicates that statistically the data set improved even although the ~ 
value decreased slightly. The y-intercept (-8.01 ± 0.1) and the coefficient of log 
BHIAso (0.82 ± 0.15) for the linear equation fall within 1 standard deviation of the 
previously reported equation [2] which shows that inclusion of SCF3 and OCF3 does 
not significantly alter the predictive equation for log BHIAso . This finding suggests 
that the SCF3 and OCF3 derivatives have excellent activity at the proposed vacuolar 
site of action and that the poor observed activity against strains of P. falciparum is 
probably the result of the low pKa1 for the SCF3 and OCF3 derivatives, which would 
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Thus the findings for these new compounds strongly support the hypothesis that the 
activity of this class of compound depends on the ability to inhibit haemozoin 
formation and to accumulate in the food vacuole through pH trapping. 
3.2.5-Chlorobenzimidazoles 
The results of SAR studies done on 5-chlorobenzimidazoles 13a, 13-14 (Figure 3.8.) 
will be reported and discussed in this section. 
Figure. 3.8. Benzimidazole target compounds tested. 
3.2.1. Acid dissociation constants 
Results for determination of pKa1 (benzimidazole ring nitrogen at 3-position) and 
pKa2 (the tertiary amine nitrogen in the side-chain) compounds 13 and 14 are shown 
in table 3.5. 
Compound 
13 3.70 ± 0.2 8.90 ± 0.02 
4 4.46:: 0.04 8.30:: 0.03 
Table 3.5. Results of pKa1 and pKa2 determinations for 13 and 14. The observed values are a mean of 
two determinations ± the standard error of the mean. 
These values agree with pKa values (pKa1 = 3.2-3.9 and pKa2 = 8.1-9.9) determined 
by Knobloch et aI., for chloroquine-like benzimidazoles 9 [88] reviewed in section 1.8. 
From these values for 13 and 14 little vacuolar accumulation can be expected (AR 13 
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3.2.2. Association constants 
Association constants for interaction with haematin were determined by 






Table 3.6. Results of log K determinations. log K was obtained using a 1: 1 association model derived 
by Mavuso [100] and values are a mean of three determinations the standard error of the mean. 
The log K values for benzimidazoles 13a. 13 and 14 are similar to previously 
published log K values for 4-aminoquinoline analogues [46]. 
3.2.3. BHIA by infrared 
Infrared spectroscopy was used to determine whether these benzimidazoles were 
able to inhibit ~-haematin formation. Results for the BHIA assay by infrared are 
shown in table 3.7. 




Table 3.7. Results obtained from BHIA infrared assay. '(+) active; (-) inactive. 
Previously unpublished studies in our laboratory showed that benzimidazole itself 
does not have ~-haematin inhibitory activity. When a chlorine is introduced in the 5-
position (13a), ~-haematin inhibitory activity is observed, although introduction of the 
aminoamidopiperazinyl side-chain at the 1-position decreases this activity drastically 
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The negative BHIA infrared assay results and the low biological activity for the 
benzimidazole targets made it unnecessary to perform the BHIAso assay on them. 
3.2.4. Biological activity 
The ICsc values for compounds 13 and 14 against both the 010 chloroquine sensitive 
strain and K1 chloroquine resistant strain of P. fa/ciparum are reported in table 3.8. 
Compound Observed against 010 Observed against K1 strain 
strain 
3 4741 ± 794 nM > 1 
14 > 10000 nM > 1 000 nM 
Table 3.8. IGso values against 010 choroquine sensitive strain and K1 chloroquine resistant strain of P. 
falciparum. The observed values are a mean of two determinations done in triplicate the standard 
error of the mean. Values greater than 10 000 nM are not reported as this indicates insignificant activity. 
The very weak or non-existent anti plasmodial activities of 13 and 14 are attributed to 
their lack of ~-haematin inhibitory activity and their poor accumulation ratio (AR) in 
the food vacuole. 
3.2.5. Preliminary study on the reduction of the side chain of benzimidazole 14 
It was hypotheSized that reduction of the secondary amide in the side-chain of 15 to 
a secondary amine would improve vacuolar accumulation via pH trapping. Results for 
compound 15 (Figure 3.8.) were obtained from an impure sample and results are 
shown in table 3.9. 
Compound Observed ICso against D10 Observed ICso against K1 
strain strain 
15 6919 ± 1753 nM 9235 ± 1130 nM 
Table 3.9. Preliminary SAR study IG50 results for compound 15. The observed values are a mean of 
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The ,lC so results for 15 appear to show some improvement in activity against the 010 
chloroquine sensitive strain and the K1 chloroquine resistant strain of P. falciparum, 
relative to 14. This indicates that activity increased after the secondary amide in the 
side-chain was reduced to a secondary amine. A pure sample of 15 is needed to 
give a better indication of antiplasmodial activity. 




J::6. ~ ~ 0 ~N, I h- /: CI N 
16 
Figure 3.9. Quinoline 16 with the piperazinyl containing side-chains. 
3.3.1. Target 16 
Results for the SAR study performed on 16 (Figure 3.9.) are shown in table 3.10. 




010 against K1 
strain 
16 4.74 ± 0.07 + 104 ±40 nM 1602 ± 448 nM 
Table 3.10. Results for 16. The observed Log K values are a mean of two determinations 1: the standard 
error of the mean and the observed ICso values are a mean of two determinations done in triplicate the 
standard error of the mean. 
In contrast to 14, 16 was active, suggesting that the combination of the 
aminoamidopiperazinyl side-chain with the 5-chlorobenzimidazole nucleus has an 
influence that eliminates p-inhibitory activity while this activity is maintained in the 4-
aminoquinoline analogue 16 (Figure 3.9.). This suggests that the relationship 
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3.4. Conclusion 
This dissertation has confirmed and extended some earlier proposed SAR for 7-
substituted-4-aminoquinolinesy,101] The linear dependence of the log ICso of 11 and 
12, corrected for vacuolar accumulation, on the ~-haematin inhibitory activity in this 
family of compounds strongly supports the hypothesis that activity results from the 
inhibition of haemozoin formation in the parasite. It also supports the proposal that 
pH trapping, supposedly via the quinoline ring nitrogen and the tertiary side chain 
nitrogen, is essential for drug activity by ensuring that the compound is concentrated 
at the site of action. The latter is strengthened by the observation of a greater 
accumulation normalized log ICso than predicted together with much lower observed 
pKa1 values for both the SCh and OCF3 derivatives. 
Where (Jm gave a marginally better correlation with pKa values in previous studies 
discussed, (Jp now gave a better correlation when pKa values for 11 and 12 are 
brought into account. A new equation can therefore be derived using (Jp, to predict 
pKa values. 
The poor or no anti plasmodial activity of the 5-chlorobenzimidazoles can be 
attributed to the combination of two factors: their low pKa values and inability to 
inhibit ~-haematin inhibitory activity once substituted in the 1-position. 
The structure-activity data collected for target 15 need to be verified with analytically 
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4. General conclusion and future studies 
4.1. Conclusion 
The objectives of this thesis as outlined in chapter 1 were: 
i. The synthesis and characterization of two novel 7-substituted-4-
aminoalkylated quinolines, N1,N1-diethYI-N2-(7 -trifuoromethylthio-4-
quinolinyl)-1 ,2-ethanediamine 11 and Nl,Nl-diethyl-N2-(7 -trifuoromethoxy-
4-quinolinyl)-1,2-ethanediamine 12 and to perform a quantitative structure 
activity analysis of them with respect to their pKa values, association 
constants with haematin, ~-haematin inhibitory activities and biological 
activities against Plasmodium fa/ciparum ; 
Ii. The synthesis of the novel side chain N-(2-aminoethyl)-2-(4-
methylpiperazin-1-yl)ethanamide 14b for incorporation into a 5-
chlorobenzimidazole template to fill the requirements for adequate 
vacuolar accumulation in P falciparum; 
iii. The investigation of the benzimidazole nucleus as an alternative template 
to the 4-aminoquinoline nucleus in chloroquine analogous anti-malarials 
by the synthesis and structure-activity studies of N-[2-(5-
chlorobenzimidazol-1-yl)ethyl]-2-( 4-methylpiperazin-1-yl)ethanamide 14 
and [2-( 5-chlorobenzimidazol-1-yl)ethyl]-[2-(4-methylpiperazin-1 
yl)ethyl]amine 15; 
IV. Establishment of the effect of the benzimidazole nucleus relative to the 
quinoline nucleus by the synthesis of N-[2-(7-chloro-4-quinolinyl)ethyl]-2-
(4-methylpiperazin-1-yl)ethanamide 16 and N-(7 -chloroquinolin-4-yl)-N'-[2-
(4-methylpiperazin-1-yl)ethyl]-ethane-1,2-diamine 17 to compare the 
bioloical results with 14 and 15. 
The 4-aminoquinolines 11 and 12 were successfully synthesized and characterized 
via a versatile 6-step route which allows for the introduction of a wide variety of 
groups in the 7-position and side chains in the 4-position. The targets 11 and 12 
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by Kaschula et al. [2] The QSAR compiled on 11 and 12, consisted of determining the 
acid dissociation constants (pKa1 and pKa2) of their basic nitrogens ; their 
associations constant (log K) for interaction with haematin; the p-haematin inhibitory 
activity (BHIA) by both the infrared assay and qualitative assay and the inhibitory 
concentration (ICso) in both the D10 and K1 strain of P. fa/ciparum. Lower than 
expected pKa1 values for 11 and 12 were reflected in the lower than expected 
observed ICso against the parasite, which supports the hypothesis that biological 
activity of 4-aminoquinolines proceeds via pH trapping in the acidic food vacuole of 
the parasite. An excellent correlation between the ICso normalized for vacuolar 
accumulation and the log BHIAso of this class compound was demonstrated. Tilis 
further supports the hypothesis that inhibition of p-haematin formation is the basis of 
biological activity in the food vacuole of the parasite. Biological activity can thus be 
predicted well based on a knowledge of the pKa values and p-haematin inhibitory 
activities of these compounds. These two compounds were also found to be active 
against chloroquine resistant parasites. 
The pKa values were found to correlate well with the Hammett constant Cip. By 
contrast, the QSAR for predicting p-haematin inhibitory activity was not useful. 
Prediction of log K for association with haematin was also poor, possibly due to the 
steric bulk of the groups at the 7-position (similar to CF3). Thus the overall ability to 
predict biological activity in this group of compounds is hampered by a lack of 
understanding of factors controlling association with haematin and inhibition of P-
haematin formation. 
Synthesis of 5-chlorobenzimidazoles via 4-chloro-1 ,2-phenylenediamine (approach 1, 
section 2.4.1.) gave regioisomers which were difficult to characterize and purify. This 
led to the use of the route via 2,5-dichloronitrobenzene - a regioselective route. The 
results of the assays performed on the benzimidazole targets 14 and 15 showed that 
they were not useful as antimalarials because of their low pKa values which causes 
decreased vacuolar accumulation in the parasite. It was also found that introduction 
of the N-(2-aminoethyl)-2-( 4-methylpiperazin-1-yl)ethanamide 14b side chain 
destabilized the p-haematin inhibitory activity since 5-chlorobenzimidazole showed P-
haematin inhibitory activity as determined by the infrared assay contrary to any of the 
5-chlorobenzimidazoles 13,14 and 15 with a side-chain in the i-position. It was 
therefore concluded that the 1-substituted-5-chlorobenzimidazoles are inactive 
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chlorobenzimidazole does suggest that 5-chlorobenzimidazoles with alternative sites 
of substitution for the side chain may potentially be active, 
The aminoamidopiperazinyl side-chain 14b was designed for the regioselective 
benzimidazole targets 14 and 15 and was successfully synthesized and 
characterized in a two step synthesis which involved characteristically difficult work-
up of amines. These properties were carried over to all intermediates in the 
regioslective 5-chlorobenzimidazole synthesis route, 
The 5-chlorobenzimidazole analogous to 4-aminoquinoline 16 was successfully 
synthesized and characterized. Reduction of the aminoamidopiperazinyl sidechain to 
produce 17 however, was unsucessfull. Compound 16 retained biological activity 
against malaria parasites, but showed strong chloroquine cross-resistance between 
the D10 strain and K1 strain of P. fa/ciparum. The weak anti-plasmodial activity of 16 
could be attributed to the long side chain as with other long side-chain analogues 
reviewed in the introduction of this thesis. 
4.2. Future work 
Extensive studies have been performed on 7-substituted 4-aminoquinolines as 
reviewed in the Chapter 1. There is now considerable understanding of the 
relationship between structure and activity in this specific class of compound. 
Nonetheless, the origin of the ~-haematin inhibitory activity of these compounds is 
still poorly understood and requires further investigation. Application of both 
experimental and computational methods to this problem need to be undertaken. In 
addition to this, the focus should shift towards a QSAR study on the 4-aminoalkyl 
side chain and its relationship to cross-resistance with chloroquine. This may permit 
a more rational selection of side chains for circumventing such cross-resistance. 
Since [2-(5-Chlorobenzimidazol-1-yl)ethyl]-[2-( 4-methylpiperazin-1-yl)ethyl]amine 15 
was not purified before testing owing to its polar character, the results from its 
biological testing is only about 70% accurate judged by 1H NMR spectra, Further 
attempts must therefore be made to purify this compound, possibly via tosylation of 
the secondary amine in the diaminopiperazinyl side-chain which would yield a less 










The 5-chlorobenzimidazoles in this study proved to be inactive against P. fa/ciparum. 
There are however many other analogues to be studied before the benzimidazole 
nucleus can be abandoned as an alternative template to the 4-aminoquinoline 
nucleus. Possible analogues to be studied includes benzimidazoles with chlorine in 
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5. Experimental 
5.1. Synthetic methods 
5.1.1. General procedures 
Thin layer chromatography (TLC) was used to monitor reactions using Merck F2554 
aluminium-backed precoated silica gel plates and these were visualized with a 
combination of ultraviolet light, iodine staining, eerie ammonium sulphate spray and 
anisaldehyde spray. Column chromatography was performed using Merck kieselgel 
60: 70-230 mesh. Melting points were obtained with a Reichert-Jung Thermovar hot 
stage microscope. Infrared spectra were recorded as dichloromethane solutions or 
as KBr discs using a Perkin Elmer Paragon 1000 FT-IR spectrophotometer. 1H and 
13C NMR spectra were recorded on a Varian VXR-200 spectrometer at 200 MHz or a 
Varian Mercury spectrometer at 300 MHz or a Varian Unity spectrometer at 400 
MHz. Spectra were recorded in deuterochloroform (CDCb) or 
deuterodimethylsulfoxide (ds DMSO) using internal standards for 1H of 6H = 7.26 ppm 
and 2.50 ppm respectivily and for 13C of Oc = 77.16 ppm and 39.52 ppm. All chemical 
shifts are reported in ppm and all coupling constants in Hz. Elemental analysis were 
performed using a Fison's Instruments Elemental Analyser EA 1108. Mass 
spectrometry was performed externally by Dr. Philip Boshoff at Cape Technicon on a 
VG Micromass instrument. 
5.1.2 Synthesis, purification and characterisation 
Ethyl 2-ethoxycarbonyl-3-(3-trifluoromethylthioanilino)propenoate (11 a) 
A mixture of 3-trifluoromethylthioaniline (1.0 g, 5.3 mmol) and diethyl 
methoxymethylene malonate (1.3 g, 5.8 mmol) was refluxed in ethanol (100 ml) for 3 
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recrystallized from ethanol and dried to give 11 a (1.9 g, 99%), mp 69°C; bH(400 MHz, 
CDCI 3) 1.29 (3H, t, J 7.0, CH3), 1.32 (3H, t, J 7.0, CH3), 4.22 (2H, q, J 7.0, CH 2), 7.15 
(1 H, m, Ar-H), 7.32 (3H, m, Ar-H), 8.38 (1 H, d, J 13.6, vinylic H), 10.97 (1 H, bd, J 
13.2, NH); be (100.6 MHz, CDCb) 14.2 (CH3 ), 14,4 (CH 3), 60.3 (CH 2), 60.6 (CHJ, 
95.1 (Q=CH), 119.2 (C-6), 124,4 (C-4), 126,4 (C-3), 129.3 (q, JC-F 308.2, SCF3), 
130.8 (C-5), 132.0 (C-2), 140.4 (C-1), 151.2 (C=QH), 165.5 (C=O), 168.9 (C=O); 
(Found: MS (HRMS) mlz 363.07429. Requires: 363.07521); (Found: C, 49.40; H, 
4.82; N, 3.87; S, 8.8%. Requires for C1sH16F3N04S: C, 49.5; H, 4,4; N, 3.8; S, 8.8%) 
Ethyl 1 ,4-dihydro-4-oxo-7 -(trifluoromethylthio)quinoline-3-carboxylate (11 b) 
11a (1.0 g, 2.7 mmol) was refluxed in diphenyl ether (10 mil for 30 minutes. The 
flask was opened during the first 10 minutes of the reaction to allow the ethanol 
formed to escape. When the reaction mixture cooled to room temperature, a white 
precipitate formed. This was filtered and washed with petroleum ether, ethyl acetate 
and methanol to remove all diphenyl ether and other impurities to give 11 b (0.6 g, 
75%) after drying, mp 265-266°C; Ymaxlcm-1 (KBr) 3150, 1637 (CO); bH (200 MHz, de 
DMSO) 1.30 (3H, t, J 7.2, CH 3), 4.25 (2H, q, J 7.2, CHz), 7.60 (1 H, d, J 4.6, H-6), 
7.98 (1 H, s, H-8), 8.25 (1 H, d, J 4.6, H-5), 8.67 (4H, s, H-2); (Found: MS mlz 317. 
Requires: M+, 317); (Found C, 49.1; H, 3.1; N, 4,4; S, 9.7%. Requires for 
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Ethyl 1 ,4-dihydro-4-oxo-7 -(trifluoromethylthio)quinoline-3-carboxylate (11 b) 
A mixture of 11b (0.9 g, 2.8 mmol) and 10% l\JaOH (10 ml) was heated at 120°C for 2 
hours. During this period all of the solid dissolved. The aq.ueous phase was then 
carefully neutralised with 10% H2S04 to avoid formation of the water-soluble 
quinolinium ion, and a white solid precipitated which was filtered off and washed with 
cold water. The solid was dried over PZ0 5 under vacuum to yield 11c (0.5 9, 70%), 
mp 233-236°C; v maxfcm·
1 (KBr) 2900, 1620; bH (300 MHz, d6 DMSO) 7.80 (1 H, dd, J 
8.4, 1.5, H-6), 8.16 (1 H, d, J 1.5, H-8), 8.37 (1 H, d,J 8.4, H-5), 8.98 (1 H, s, H-2), 
13.44 (1 H, bs, COOH), 14.85 (1 H, bs, Ar-OH); be (75.5 MHz, ds OM SO) 108.5 (C-3), 
125.6 (Ar-CH), 126.3 (C-5), 126.8 (C-8), 129.3 (q, JC.F 308.3, SCF3), 129.5 (C-4a), 
131.3 (C-6) , 139.5 (C-8a), 146.3 (C-2), 165.7 (COOH), 177.8 (C-4); (Found: MS 
(HRMS) m/z 289.00182. Requires for C10HsF3N03S: 289.00205). 
7 -(Trifluoromethylthio)quinolin-4-one (11 d) 
11c (0.8 g, 2.9 mmol) was added to diphenyl ether (8 ml) and the mixture refluxed in 
a preheated oil bath. After 30 minutes the reaction was allowed to cool when all the 
solid had dissolved. A precipitate formed which was filtered, and washed with 
petroleum ether and cold ethyl acetate to remove all diphenyl ether to yield 11 d (0.4 
g, 68%), which was recrystallized from methanol and ethyl acetate, mp 214-215°C; 
v max/cm·
1 (KBr) 2943, 1630; DH (300 MHz, d6 OMSO) 6.12 (1 H, d, J 7.2, H-3), 7.52 
(1H, dd, J 8.4,1.2, H-6), 7.92 (1H, d, J 1.2, H-8), 7.99 (1H, d, J 7.2, H-2), 8.19 (1H, d, 
J 8.4, H-5), 11.89 (1 H, bs, Ar-OH); be (100.6 MHz, ds OMSO) 109.6 (C-3), 125.6 (C-
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SCF3), 140.1 (C-8a), 140.2 (C-2), 176.06 (C-4); (Found: MS (HRMS) mlz 245.01228. 
Requires for C1OHsF3NOS: 245.01222). 
4-Chloro-7 -trifluoromethylthioquinoline (11 e) 
A mixture of 11d (0.4 g, 1.4 mmol), phosphorus oxychloride (1 ml, 11.4 mmol) and 
phosphorus pentachloride (0.3 g, 1.6 mmol) was refluxed under N2 at 120°C for 30 
minutes. The reaction mixture was then poured into cold aq. 10% NaOH (1 M, 50 ml) 
and the white precipitate was filtered and washed with water. The solid was then 
dissolved in ethyl acetate (100 ml), dried (MgS04) and the solvent removed in vacuo. 
Recrystallization from petroleum ether gave 11e (0.3 g, 88%), mp 69°C; OH (400 
MHz, CDCb) 7.57 (1 H, d, J 4.7, H-3), 7.83 (1 H, dd, J 9.0, 1.7, H-6), 8.28 (1 H, d, J 
9.0, H-5), 8.48 (1 H, d, J 1.7, H-8), 8.85 (1 H, d, J 4.7, H-2); Bc (75.5 MHz, CDC!:,) 
122.8 (C-3), 122.9 (C-7), 125.7 (C-5), 127.6 (C-4a), 129.6 (q, JC-F 308.6, SCF3 ), 
133.2 (C-6), 138.0 (C-8), 142.9 (C-4), 149.0 (C-8a), 151.3 (C-2); (Found: MS (HRMS) 
mlz 262.97808. Requires for C10HsCIF3NS: 262.97833). 
tf-(7 -Trifluoromethylthio-4-quinolinyl)-N1 ,N1-diethyl-1 ,2·ethanediamine (11) 
11e (0.2 g, 1.0 mmol) and N,N-diethylethylenediamine (3 ml) were heated together in 
a sealed tube under N2 at 140°C for 4 hrs. Aq. 10% NaOH (2 ml) was added to the 
product and the resulting yellow precipitate was then extracted into dichloromethane 
(3 x 100 ml). The solvent was dried (MgS04 ) and removed under reduced pressure 
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dichloromethane (2:8) as eluent to give 11 (OA, 80%), mp 110-111 DC; bH (400 MHz, 
COCh) 1.08 (6H, t, J 7.3, 2xCH3), 2.61 (4H, q, J 7.3, 2xCH2)' 2.83 (2H, t, J 6.2, CH 2-
~), 3.28 (2H, q, J 6.2, CHra), 6.21 (1 H, bs, NH), 6A3 (1 H, d, J 5.1, H-3), 7.61 (1 H, 
dd, J 9.0, 1.8, H-6), 7.72 (1 H, d, J 9.0, H-5), 8.30 (1 H, d, J 1.8, H-8), 8.58 (1 H, d, J 
5.1, H-2); oe (100.6 MHz, COC(3) 12.3 (CH 2QH 3), 39.9 (CH 2-a), 46.7 (Q.H 2CH 3), 50.8 
(CH2-tJ), 100.3 (C-3), 120.3 (C-7), 121.2 (C-5), 125.2 (C-4a), 129.8 (q, JC-F 308.1, 
SFC3), 130.3 (C-6), 138.5 (C-8), 148.7 (CA), 149.9 (C-8a), 152.5 (C-2); (Found: MS 
mlz (HRMS) 344.14095 (M+H). Requires for C16H21F3N3S (M+H): 344.14082). 
Ethyl 2-ethoxycarbonyl-3-(3-trifluoromethoxyanilino )propenoate (12a) 
A mixture of 3-trifluoromethoxyaniline (1.0 g, 5.6 mmol) and diethyl 
methoxymethylene malonate (1.3 g, 6.2 mmol) was refluxed in ethanol for 3 hours 
after which the solvent was removed in vacuo. The resulting solid was recrystallized 
from ethanol and dried to give 12a (1.8 g, 93 %), mp 42-43°C; OH (400 MHz, CDC(3) 
1.30 (3H, t, J 7.3, CH 3) 1.30 (3H .. t, J 7.3, CH 3 ), 4.24 (2H, q, J 7.3, CH 2), 4.24 (2H, q, 
J 7.3, CH 2), 6.95 (2H, m, H-2 and H-4), 7.35 (1H, t, J 7.5, H-6), 7.33 (1H, m, H-5), 
8AO (1H, dd, J 13.2, 7.7, C=Q.H), (1H, d, J 13.2, NH); Be (100.6 MHz, CDCI3) 14.2 
(CH 3), 14.3 (CH 3), 60.3 (CH 2), 60.6 (CHz), 95.0 (Q.=CH), 109.9 (C-5), 115.2 (C-6), 
116.6 (C-4), 120A (q, JC-F 257.9, OCF3), 131.1 (C-2), 140.9 (C-1), 150.3 (C-3), 151.2 
(C=Q.H), 165A (C=O), 168.9 (C=O); (Found: MS (HRMS) mlz 347.09786. Requires 
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Ethyl 1 ,4-dihydro-4-oxo-7 -{trifluoromethoxy)quinoline-3-carboxylate (12b) 
12a (1.0 g, 2.8 mmol) was refluxed in diphenyl ether (10 ml) for 15-30 minutes. The 
flask was opened during the first 10 minutes of the reaction to allow the ethanol 
formed to escape. When the reaction mixture cooled to room temperature, a white 
precipitate formed. This was filtered and washed with petroleum ether, ethyl acetate 
and methanol to remove all diphenyl ether and other impurities, to give 12b after 
drying, (0.6 g. 73 %), mp 234-235°C; vmax/cm-
1 (KBr) 2918, 1622; bH(400 MHz, ds 
DMSO) 1.26 (3H, t, J 6.5, CH 3), 4.25 (2H, q, J 7.3, CH2), 7.32 (1 H, d, J S.7, H-5), 
7.53 (1 H, s, H-S) 8.27 (1 H, d, H-6), 8.50 (1 H, s, H-2); (Found: MS (HRMS) m/z 
301.05637. Requires for C13H1oF3N04: 301.05619). 
1,4-Dihydro-4-oxo-7-(trifluoromethoxy)quinoline-3-carboxylic acid (12c) 
A mixture of 12b (1.1 g, 3.6 mmol) and 10% NaOH (10 ml) was heated at 120°C for 2 
hours. During this period, all of the solid dissolved. On cooling, the organic 
impurities were extracted into ethyl acetate (3 x 100 ml). The aq.ueous phase was 
then carefully neutralised with 10% H2S04 to avoid formation of the water-soluble 
quinolinium ion, and a white solid precipitated which was filtered and washed with 
cold water. The white solid was dried over P20S under vacuum to yield 12c (0.8 9 
,84%), mp 274-279°C; Ymax/cm-1 (KBr) 2930, 1634; bH (300 MHz, de DI\I1S0) 7.46 
(1H, dd. J 8.7,1.2, H-6), 7.73 (1H, d, J 1.2, H-8), 8.41 (1H, d, J 8.7, H-5), 8.87 (1H, s, 
H-2); be (75.5 MHz. d6 DMSO) 10S.2 (C-3), 110.6 (C-S), 118.4 (C-6), 119.8 (q, JC-F 
2S8.7 , OCF3),123.1 (C-4a), 128.2 (C-S), 141.1 (C-8a), 146.8 (C-2), 151.3 (C-7), 
166.1 (COOH), 177.3 (C-4); (Found: MS (HRMS) m/z 273.02454. Requires for 
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7 -(Trifluoromethoxy)quinolin-4-one (12d) 
F Fro~ 0 .. 
X ~ . 
F ° \l r-: 
12c (0.8 g, 3.0 mmol) was added to diphenyl ether (8 ml) and the mixture refluxed in 
a preheated oil bath. After 30 minutes the reaction was allowed to cool when all the 
solid had dissolved. A precipitate formed which was filtered, and washed with 
petroleum ether and cold ethyl acetate to remove all diphenyl ether to yield 12d (0.6 
g, 86%), which was recrystallized from methanol and ethyl acetate, mp 224-227°C; 
v max/cm·
1 (KBr) 2930, 1639; bH (400 MHz, d6 DMSO) 6.04 (1 H, d, J 7.6, H-3), 7.27 
(1 H, d, J 9.1, H-5), 7.47 (1 H, d, J 1.4, H-8), 7.92 (1 H, dd, J 9.1, 1.4, H-6), 8.16 (1 H, d, 
J 7.6, H-2), 11.79 (1 H, bs, Ar-OH); be (75.5 MHz, de DMSO) 109.8 (C-3), 110.1 (C-8), 
116.5 (C-6), 120.6 (q, JC•F 256.7 , OCF3) 125.1 (C-4a), 128.8 (C-5), 140.9 (C-8a), 
141.6 (C-2), 151.0 (C-7) , 176.8 (C-4); (Found: MS (HRMS) m/z 229.03509. Requires 
for ClO H6F3N02: 229.03506). 
4-Chloro-7-trifluoromethoxyquinoline (12e) 
Cl F Fm~ ~X . ~ /-
F 0 N 
A mixture of 12d (0.5 g, 2.1 mmol), phosphorus oxychloride (1.6 ml, 16.8 mmol) and 
phosphorus pentachloride (0.5 g, 2.S mmol) was refluxed under N2 at 120°C for 30 
minutes. The reaction mixture was then poured into cold aq. 10% NaOH (1 M, 50 ml) 
and the white precipitate filtered and washed with water. The solid was then 
dissolved in ethyl acetate (100 ml), dried (MgS04 ) and the solvent removed in vacuo. 
Recrystallization from petroleum ether gave 12e (0.5 g, 89%), mp 3]oC; 6H (400 
MHz, CDC!,) 7.50 (1H, dd, J 9.0,2.6, H-6), 7.51 (1H, d, J 4.7, H-3), 7.97 (1H, d, J 
2.6, H-8), 8.28 (1 H, d, J 9.0, H-S), 8.81 (1 H, d, J 4.7, H-2); be (100.6 MHz, CDCI3) 
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126.5 (C-5), 149,8 (C-4), 150,6 (C-8a), 151.4 (C-2), 171.1 (C-7); (Found: MS (HRMS) 
mlz 247,00101. Requires for ClOHsF3CINO: 247,00117). 
N2 _(7 -Trifluoromethoxy-4-quinolinyl).N1 ,N1.diethyl-1 ,2-ethanediamine (12) 
( 
F F m'" H~N'-./ 
X /:/".-:;. 
F 0 N 
12e (0.2 g, 1,0 mmol) and N,N-diethylethylenediamine (3 ml) were heated together in 
a sealed tube under N2 at 140°C for 4 hrs. Aq. 10% NaOH (2 mil was added to the 
product and the resulting yellow precipitate was then extracted into dichloromethane 
(3 x 100 ml). The solvent was dried (MgS04), removed under reduced pressure and 
the residue chromatographed on silica gel using methanol and dichloromethane (10-
20:90-80) as eluent to give 12 (0.4 g, 80%), mp 110-111 °C; OH (300 MHz, CDC3) 
1,08 (6H, 1. J 6.9, CH 3), 2.61 (4H, q, J 6.9, CH 2), 2.83 (2H, t, J 5.4, CH2-~), 3.24 (2H, 
q, J 5.4, CH2-a), 6.13 (1H, bs, NH), 6.38 (1H, , J 5.1, H-3), 7.27 (1H, , J 9.0, H-6), 
7.75 (1H, d, J 9,0, H-5), 7.98 (1H, d, J 0,6, H-B), 8.59 (1H,d , J 5,1, H-2); be (100.6 
MHz, COCh) 12.3 (CH2QH]), 39.9 (CH2-~)' 46.7 (QH2CH]), 50.B (CH2-a), 99.5 (C-3), 
117,6 (C-8), 11B.2 (C-6), 120,1 (q, JC-F 258.0, OCF] ),121,8 (C-5), 149.4 (C-Ba), 
150.0 (C-4), 152.6 (C-2), 158.5 (C-7); (Found: MS (HRMS) mlz 328.16392. Requires 
for C'6HzoF3N30 (M+H): 328.16366). 







4-chloro-1,2-phenylenediamine (4.8 g, 33 mmol) was dissolved in dry 
dichloromethane (50 ml). Trimethylorthoformate (8,5 ml, 66 mmol) was added and 
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After 4 hrs the reaction mixture was poured into aq. Na2C03 ( 50 ml, 1 M). The 
compound was then extracted into ethyl actetate (3 x 100 ml) followed by 
dichloromethane (1 x 100 ml), and the organic extracts dried (MgS04)' The solvent 
was removed under reduced pressure and the oily residue chromatographed on 
silica gel using equal parts of petroleum ether and ethyl acetate as eluent to yield 13a 
(4,8 g, 94%) as a yellow solid which was recrystallized from ethyl acetate and 
petroleum ether, mp 122°C; OH (400 MHz, CDC I:» 7.26 (1 H, dd, J 8,8, 1.8, H-6), 7.55 
(1 H, d, J 8.8, H-7), 7.63 (1 H, d, J 1.8, H-4), 8.16 (1 H, s, H-2), 10.40 (1 H, bs, NH); Oc ( 
75.5 MHz, CDCb) 115.3 (C-7), 116.2 (C-4), 123.6 (C-6), 128.7 (C-5), 136.1 (C-3a/C-
7a), 138,2 (C-3a/C-7a), 141,7 (C-2); {Found: MS (HRMS) mlz 152,01374. Requires 
for C7HsCIN2: 152.01412}. 
(5-Chlorobenzoimidazol-1-yl)ethanoic acid ethyl ester (13b) 
NaH (1.3 g, 32 mmol) was added to a cooled solution (O°C) of 13a (3.2 g, 21.3 mmol) 
in dry tetrahydrofuran (100 ml). The mixture was stirred for 1 hr during which a 
colour change of orange to green was observed. The mixture was then cooled to -
78 DC and ethyl bromoacetate (4.3 g, 25.6 mmol) was slowly added over 10 minutes. 
After 30 minutes the reaction mixture was quenched with saturated ammonium 
chloride solution. The product was then extracted with ethyl acetate (3 x 100 ml) and 
the extracts dried (MgS04)' All solvent was then removed under reduced pressure 
and the product recrystallized from ethyl actetate to yield 13b (3.0 g, 60%); OH (400 
MHz, CDCI3) 1.24 (3H, t, J 7.3, CH 3), 4.20 (2H, q, J 7.3, OCH2), 4.83 (2H, s, NCH2), 
7.20 (1 H, d, J 9.0, H-7), 7.24 (1 H, dd, J 9.0, 2.1, H-6), 7.77 (1 H, d, J 2.1, H-4), 7.90 
(1H, s, H-2); Oc (100.6 MHz, CDCh) 14.0 (CH3), 46.2 (NCH 2), 62.4 (OCH 2), 110,2 (C-
7),120.2 (C-4), 121,7 (C-3a), 124.0 (C-6), 128.3 (C-5), 132.7 (C-7a), 144.7 (C-2), 
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2-(5-Chlorobenzoimidazol-1-yl)-N-(2-diethylaminoethylethanamide (13) 
13b (0.5 g, 2.1 mmol) was stirred in N,N-diethylethy!enediamine (10ml) in a sealed 
vessel under N2 at 100°C for 45 minutes. The excess N ,N-diethylethylenediamine 
was removed under reduced presure. The resulting oil was then subjected column 
chromatography on silica gel with a mixture of dichloromethane and methanol (80:20) 
as eluent. This yielded a non-crystalline solid, 13 (0.5 g, 73%); OH (400 MHz, COCI3) 
0.71 (6H, t, J 7.2, CH3), 2.28 (4H, q, J 7.2, QH 2CH3), 2.40 (2H, t, CH2), 3.24 (2H, m, 
NHCH2), 4.79 (2H, s), 6.60 (1 H, bs, NH), 7.24 (1 H, dd, J 8.6, 2.0, H-6), 7.36 ('I H, d, J 
2.0, H-4), 7.68 (1 H, d, J 8.6, H-7), 7.90 (1 H, s, H-2); (Found: MS (HRMS) mlz 
309.14838. Requires for C15Hn CIN40: 309.14821 (M+H)). 
(4-Methylpiperazin-1-yl)ethanoic acid ethyl ester (14a) 
N-methylpiperazine (10 ml, 90 mmol) and triethylamine (15 ml) were added together 
with dichloromethane as solvent and cooled to DoC. Ethyl bromoacetate (11 ml, 99 
mmol) was slowly added over 10 minutes. Formation of the white hydrobromide salt 
of HOnig's base was immediately observed. After 3 hrs the reaction mixture was 
filtered to remove the salt formed. The solvent was removed under reduced pressure 
and the crude product vacuum distilled (b.p. 89°C, 0.05 mm Hg) to yield, a colourless 
oil, 14a (12 g, 75%); OH (400 MHz, COCh) 1.19 (3H, t, J 7.3, CH 3 ), 2.21 (3H, s, 
NCH3 ), 2.42 (4H, bs, 2xCHr a), 2.55 (4H, bs, 2xCH 2-b), 3.13 (2H, S, CHrc), 4.14 
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54.7 (2xCH r b), 59.4 (CH2-C), 60.4 (OCH 2), 170.1 (C:::O); (Found: MS (HRMS) m/z 
186.13694. Requires for C9H18N202: 186.13682). 
N-(2-Aminoethyl)-2-(4-methylpiperazin-1-yl)ethanamide (14b) 
I 
N 8( "y 
b /b NyH e c N~NH 
d 2 
o 
14a (11.5 g, 61 mmol) and excess ethylenediamine (12 ml) were stirred in a sealed 
tube under N2 at 120°C for 4 hrs. The excess ethylenediamine was removed under 
reduced pressure and the resulting crude product was vacuum distilled (b.p. 67°C, 
0.05 mm Hg) to yield a yellow oil, 14b (8.8 g, 70%); bH (400 MHz, CDCb) 1.75 (2H, 
bs, NH2), 2.23 (3H, S, NCH3), 2.40 (4H, bs, 2xCHr a), 2.51 (4H, bs, 2xCH 2-b), 2.77 
(2H, t, J 5.8, CHz-e), 2.96 (2H, s, CHrc), 3.26 (2H, q, J 5.8, CHz-d), 7.36 (1 H, bs, 
NH); be (75.5 MHz, CDCI3) 38.8 (CHz-d), 45.9 (NCH3 ), 53.3 (2xCHz-a), 53.5 (2xCHz-
b), 55.1 (CHre), 61.3 (CH 2-c), 142.0 (C:::O); (Found: MS (HRMS) m/z 200.16368. 
Requires for C9H20N40: 200.16370). 
N-[2-( 4-Chloro-2-nitrophenylamino )ethyl]-2-( 4-methyl pi perazi n-1-yl)ethanamide 
(14c) 
a 
H 0 b~N/ 
6 I d II I I 
V. ~1 N~ /~N~a 41 2 e ~ C b ~ H Cl 3 N02 
A solution of 14b (12 g, 63 mmol) and 2,5-dichloronitrobenzene (13 g, 69 mmol) in 
dimethylformamide were refluxed. After 3 hrs the reaction mixture was cooled and 
basified with 10% NaOH (1 M, 80 ml). The product was then extracted into ethyl 
acetate (3 x 100 ml). After a charcoal clean the solvent was removed under reduced 
pressure and the solid recrystallized from ethyl acetate and petroleum ether to yield 
orange crystals of 14c (8.9 g, 40%), mp 86-88°C; bH (400 MHz, CDCI3) 2.27 (3H, s, 
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m, 2xCH2-d,e}, 6.94 (1 H, d, J 9.5, H-6), 7.33 (1 H, dd, J 9.5, 2.9, H-5), 7.44 (1 H, bs, 
NH), 8.04 (1 H, bs, NH-Ar) 8.14 (1 H, d, J 2.9, H-3); Oc (100.6 MHz, CDCI3) 38.1 (CH2 -
d), 42.4 (CH 2-e), 45.8 (NCH 3), 53.4 (CHrb), 55.0 (CH 2-a), 61.2 (CH 2-c), 115.1 (C-3), 
120.5 (C-6), 125.9 (C-5), 132.0 (C-4), 136.3 (C-2), 143.8·(C-1), 171.0 (C=O); (Found: 
MS (HRMS) m/z 356.14854 (M+H). Requires for C1sH23CINs03 (M+H): 356.14893). 
N-[2-(2-Ami no-4-ch lorophenylamino )ethyl]-2 -( 4-methyl pi perazi n-1-
yl)ethanamide (14d) 
14c (2.9 g, 8.3 mmol) was dissolved in cone. HCI (8 M, 2 ml) and added to a chilled 
solution of stannous chloride (7.5 g, 33 mmol) in conc.HCI (8 M, 5 ml). After 2 hrs 
the reaction mixture was poured onto ice and basified by adding NaOH (2.4 g, 6 
mmol) pellets to the solution. The product was extracted into ethyl acetate (2 x 100 
ml) followed by dichloromethane (1 x 100 ml) and the organic extract dried (MgS04)' 
The solvent was removed under reduced pressure and the solid recrystallized from 
ethyl acetate to yield purple crystals of 14d (2.5 g, 94%), mp 123-124°C; 8H (400 
MHz, CDCI3) 2.26 (3H, s, NCH3), 2.38 (4H, bs, 2xCH2-a), 2.53 (4H, m, 2xCH 2-b), 
2.99 (2H, S, CH2-C), 3.24(4H, m, CHz-e), 3.45 (1 H, bs, f\IH 2), 3.56 (2H, t, J 6.24, CH 2-
d), 3.79 (1 H, bs, NH-Ar), 6.49 (1 H, d, J 8.3, H-6), 6.65 (1 H, d, J 2.4, H-3) 6.69 (1 H, 
dd, J 8.3, 2.4, H-5), 7.42 (1H, bs, I\JH); Oc (100.6 IVIHz, CDCI3) 38.8 (CHTd), 44.9 
(CHz-e), 45.9 (NCH3), 53.5 (CH2-b), 55.1 (CH 2-a), 61.4 (CH 2-c), 112.1 (C-3), 115.8 
(C-6), 119.6 (C-5), 123.3 (C-4), 135.6 (C-2), 150.1 (C-1), 171.4 (C=O); (Found: MS 
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N-[2-( 5-Chlorobenzoimidazol-1-yl)ethyl]-2-( 4-methyl pi perazin-1-yl)ethanamide 
(14) 
14d was added to a 10% solution in water of formic acid (3.7 mmol). The mixture 
was then acidified with cone. HCI (8 M, 1 ml) and heated to 120°C for 2.5 hrs. After 
cooling to room temperature, the product was extracted into ethyl acetate (3 x 100 
ml) and the organic extracts dried (MgS04 ). All solvent was removed by reduced 
pressure and the product recrystallized from ethyl acetate to yield pink crystals of 14 
(0.9 g, 87%), mp 156-157°C; OH (300 MHz, CDCI3) 2.19 (3H, s, NCH 3), 2.19 (4H, bs, 
CHra), 2.36 (4H, t, CH 2-b), 2.93 (2H, 5, CHrc), 3.67 (2H, q, J 5.9, CH2-d), 4.36 (2H, 
1, J 5.9, CH2-e), 7.19 (1H, bs, NH), 7.26 (1H, dd, J 8.8,1.8, H-6), 7.33 (1H, d, J 8.8, 
H-7), 7.78 (1H, d, J 1.8, H-4), 7.84 (1H, s, H-2) ; Dc (100.6 MHz, COCh) 39.2 (C-d), 
44.2 (C-e), 46.0 (NCH3), 53.6 (C-b), 55.0 (C-a), 61.3 (C-c), 110.4 (C-7), 120.5 (C-4), 
123.8 (C-6), 128.2 (C-5), 132.7 (C-7a), 144.1 (C-2), 144.8 (C-3a), 171.3 (C=O); 




A solution of 14c (0.9 g, 2.6 mmol) in anhydrous tetrahydrofuran was slowly added to 
a chilled suspension of lithium aluminium hydride (0.5 g, 13 mmol) in anhydrous 
tetrahydrofuran under Nz in a cyclization tube. The mixture was stirred at room 
temperature for 1 hr and then heated to 70°C for 60 hrs. On cooling, the product was 
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ml) cooled in an ice-water bath. This mixture was stirred until! the suspension turned 
white and then filtered through Celite to remove the salts. The solvent was dried 
(MgSO<l) and removed under reduced pressure to yield a mixture of 14c and the 
reduced form of the amide 14e (0.8 g) as a purple oily residue, which could not be 
purified owing to its very polar character. The crude product was added to methanoic 
acid (0.2 g, 3.7 mmol). The mixture was then acidified with cone. HCI (S M, 1 ml) and 
heated to 120°C for 1 hr. On cooling the excess water and methanoic acid were 
azeotropically removed with toluene under reduced pressure. The crude material 
was chromatographed with a mixture of dichloromethane, methanol and ammonia 
solution (80: 19: 1) as eluent, to give 15 ( 0.2 g, 49%); OH ( 400 MHz, CDCI 3 ) 2.49 (3H, 
s, NCH3), 2.59 (2H, J 6.0, CH2), 2.63 (4H, bs, H-a), 2.71 (4H, bs, H-b), 2.79 (2H, t, J 
6.0, CH2), 3.17 (2H, t, J 6.0, CH2), 4.44 (2H, t, J 6.0, CH2), 5.70 (1H,m bs, NH), 7.23 
(1 H, dd, J 8.S, 2.0, H-6), 7.42 (1 H, d, J 8.8, H-7), 7.61 (1 H, d, J 2.0, H-4), 8.12 (1 H, s, 
H-2); (Found: MS (HRMS) mlz 322.17987 (M+H). Requires for C16H2sCINs (M+H): 
322.17984). 
N-[2-(7 -Chloro-4-quinolinyl)ethyl]-2-(4-methylpiperazin-1-yl)ethanamide (16) 
A mixture of 4,7-dichloroquinoline (0.5 g, 2.6 mmol), 14b (0.5 g, 2.6 mmol) and 
potaSSium fluoride (0.2 g, 3.3 mmol) were dissolved in dimethylformamide in a sealed 
tube under Nz and heated to 150°C for 5 hrs. On cooling, the reaction mixture was 
poured into water, basified with potassium hydroxide solution (5 ml, 1 M) and the 
product extracted into ethyl acetate (3 x 100 ml). The solvent was removed under 
reduced pressure and the solid recrystallized from ethyl acetate to yield 16 (0.5 g, 
58%) as a crystalline solid, mp 197-199°; OH (400MHz, d6 DMSO) 2.08 (3H, s, NCH3), 
2.23 (4H, bs, H-a), 2.35 (4H, bs, H-b), 2.82 (2H, s, H-c), 3.34 (4H, H-dle) , 6.55 (1H, 
d, J 5.6, H-3), 7.32 (1H, t, NH-Ar), 7.43 (1H, dd, J 8.8,2.0, H-6), 7.77 (1H, d, J 2.0, H-
8),7.91 (1H, t, NH), 8.17 (1H, d, J S.8, H-5), 8.39 (1H, d, J 5.6, H-2); oe (100.6 MHz, 
d6 DMSO) 37.0 (C-d), 42.2 (C-e), 45.6 (NCH 3 ), 52.S (C-b), 54.4 (C-a), 61.3 (C-c), 
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(C-8a), 150.0 (C-4), 151.8 (C-2), 169.9 (C=O); (Found: MS (HRMS) mlz 362.17468 
(M+H). Requires for C1sH2sCINsO (M+H): 362.17475). 





m4 e d I I 6 ~ ~ 3 ~N",-I / ~ CI N 2 
8 
A solution of 16 (0.6 g, 1.6 mmol) in anhydrous tetrahydrofuran was slowly added to 
a suspension of lithium aluminium hydride (0.3 g, 8 mmal) in anhydrous 
tetrahydrofuran cooled in an ice-water bath under N2 in a cyclization tube. The 
mixture was stirred at room temperature for 1 hr and then heated to 70°C for 3hrs. 
On cooling, the product was slowly poured onto a mixture of tetrahydrofuran, 
triethylamine and water (8:1:1) cooled in an ice-water bath. This mixture was stirred 
until the aluminium salts formed and then filtered through Celite. The organic 
extracts were dried (MgS04) and the solvent removed under reduced pressure to 
yield (0.3 g) a colourless oily residue. The spectral data for this compound did not 
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5.2. Experimental- Physical methods 
5.2.1. ~-Haematin inhibitory Activity 
The formation of ~-haematin can be induced by non-biological conditions in the 
laboratory, i.e. in the absence of proteins, peptides etc. The formation is found to 
occur spontaneously at 60-65°C in a 0.1-8.0 M acetate solution and pH 4.2-5.0. 
Quinolines such as quinine, chloroquine and amodiaquine with antimalarial activity 
block ~-haematin formationJ45] 
Two assays were used to determine the ~-haematin inhibitory activity (BHIA) of the 
target compounds synthesized for the purpose of this dissertation. First a qualitative 
assay was performed to establish whether the novel anti plasmodial target 
compounds have ~-haematin inhibitory activity. Thereafter a quantitative assay was 
performed to establish at how many equivilants of the compounds 50% of ~-haematin 
formation was inhibited. 
5.2.1.1. Qualitative ~-haematin formation inhibition assay 
For this assay described by Egan et al (45] haematin was obtained dissolving 15 mg of 
haemin in 3 ml of 0.1 M NaOH. This solution was stirred in a glass titration cell 
connected to a bath, thermostatted at 60°C. To the solution was added 0.30 ml of 
1.0 M HCI and 1.71 ml of 12.9 M acetate (pH 5) pre-incubated at 60a C. The reaction 
mixture was removed from the cell after 30 minutes, cooled on ice for 5 minutes and 
filtered on an 8 !J.m cellulose acetate Millipore filter type SC and extensively washed 
with water. The solid was removed and dried over silica gel and phosphorous 
pentoxide for 48 hours at room temperature. This served as the blank for the 
experiment. In separate experiments, all compounds tested for ~-haematin inhibitory 
activity were each added at three equivalents to haematin to the solution under the 
same conditions as described above. The compound was added to the reaction 
mixture prior to acidification. Chloroquine was used as a control in a separate 
experiment. Infrared spectra were obtained form discs of each dried solid (2mg) in a 










Chapter 5: Experimental - Physical Methods 5.17 
Infrared spectroscopy is used for the characterization of ~-haematin because it 
discriminates clearly between haematin and ~-haematin and because little material is 
necessary for this unlike the alternative method of x-ray powder defraction which 
requires approximately 200mg of sample for the equipment available. This is 
impractical, as the scale of synthesis of the compounds synthesized is frequently 
small. 
Two dominant sharp peaks are observed in the infrared spectra of ~-haematin in the 
1700-1200 cm,1 region in contrast to the corresponding region in haematin spectra. 
The peak at 1662 ± 2 cm,1 is due to C=O while the C-O bond gives rise to the other 
peak at 1210 ± 1 cm-1. These are both from the iron coordinated carboxylate 
group.[102] 
5.2.1.2. Quantitative ~-haematin inhibitory activity assay 
The quantitative 0-haematin inhibitory activity assay determines the number of 
equivalents of a compound required to inhibit 50% of ~-haematin formation. 
An assay recently developed by Egan and Ncokazi was used where the method 
described in section 1 for ~-haematin formation was adapted for a small-scale 
reaction. The assay was kindly conducted by Mr Kanyile Ncokazi. The reaction was 
performed in an Eppendorf tube and the total reaction volume was kept at 50 1-11. The 
content consisted of 30.0591-11 of a 1.66 x 10,3 M haematin stock solution, 3.05 1-11 of a 
particular drug stock solution and 17.7 4 ~tI 12.9 M acetate solution, which was pre-
incubated in a thermostatted bath. In this new assay 19.950 ml of pyridine solution is 
added to the reaction mixture after 1 hour of incubation at 60°C in a thermostatted 
bath. This was followed by the addition of HCI (200 1-11, 0.1 M) and 500 1-11 chloroform 
to aid the extraction of haematin. The pyridine coordinates with the iron of any free 
haematin present in the reaction mixture and forms a pink colored complex. The 
concentration of this coordinated complex was measured using colorimetric visible 
spectrophotometry at a wavelength of 405 nm. The pyridine cannot coordinate with 
the iron in !3-haematin. The assay was done in triplicate for compounds 11, 12 and 
chloroquine which served as a control. 
Instruments that were used include Crison micropH 2000 pH-meter to determine pH 
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calibrate the meter before use. Eppendorf Research micropipettes were used to 
transfer accurate volumes. Weighing was done either with a Precisa 400 M or 
Sartorius scale. A Varian Cary 100 Conc UV-vis spectrophotometer was used to 
collect the spectral data. 
The 1.66 x 10-3 M haematin stock solution was prepared by weighing Sigma-Aldrich 
haematin (10.845 mg, 1.66 x 10-2 mol) and dissolving it in a 0.1 M solution of NaOH, 
which was made up volumetrically in a 10 ml volumetric flask. 
The 0.2 M HEPES buffer solution was made by dissolving Sigma-Aldrich HEPES salt 
(11.915 g, 0.05 mole) in less than 250 ml distilled water and adjusting the pH with a 
concentrated solution of NaOH to 7.50. The solution was then carried over to a 250 
ml volumetric flask and made up volumetrically with distilled water. 
Compounds 1(5.6 mg, 0.01mmole), 2 (5.3 mg, 0.01mmole) and chloroquine 
diphosphate (8.4 mg, 0.01 mmole) were weighed and dissolved in 1.0 M HCI to yield 
0.1 M solutions. Dilutions were made with 1.0 M HCI to give ten different equivalents 
relative to haematin in the reaction mixture, ranging from 0.5 to 10 equivalents. 
Finally a pyridine solution was made by adding 50 ml of HEPES buffer solution to 
100 ml of pyridine and making it up volumetrically to 1 L with distilled water. 
5.2.2. pKa determination 
pKas were determined in duplicate for compounds 1-1 by potentiometric titration [1031. 
Distilled water, boiled to remove any CO2• was used to make all solutions for the 
titration. A 0.1003 M NaOH solution was prepared from Merck Titrisol ampoules and 
stored under an atmosphere of N2 (g) in high-density glass bottles. The solution was 
standardized against recrystallized potassium hydrogenphthalate and used within 
one week of preparation or discarded. A 0.1005 M HCI solution was also prepared 
from ampoules and standardized against recrystallized sodium tetraborate. The 
compounds were weighed directly into the titration vessel (0.01-0.03 mmole) and 
protonated with HC!. The volume of the solution in the vessel was then made up to 
20 ml with 0.15 M NaCI to ensure a constant ionic background. The titration vessel 
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potential of the mixture was measured by a Metrohm 6.0222.100 combined 
electrode. The electrode was calibrated before use by buffer solutions with pH 4.00, 
6.85 and 9.18. Titration with the NaOH solution was then performed by addition of 
100 increments with a Dosimat automatic burette to a total volume sufficient to pass 
equivalence point. The 100 data points were then analyzed using the EST A 
program. [104] 
5.2.3. Drug-haematin association constants 
Association constants was measured by titration of a haematin solution in HEPES 
buffer (pH 7.5) and DMSO (40% v/v) with drug stock solutions also in HEPES buffer 
and DMSO. The data were fitted to a model [100] based on a 1:1 haematin drug 
stoichiometry. 
The haematin (8 mg, 0.01 mmol) stock solution was prepared in a DMSO (10 ml). 
Hepes buffer (pH7.5) was prepared as described in section (1). This solution was 
kept away from light to prevent photodegradation. A stock solution (2 mM) was 
prepared in eppendorf tubes for each of compounds 10-12, 12b and 13-16 by 
dissolving them in 800 )11 of DMSO adding 200 )11 of HEPES buffer solution and 
making this up in a 2 ml volumetric flask. The analyte in each cuvet before titration 
consisted of 4 )11 of haematin stock solution, 200 )11 of HEPES buffer solution, 796 ,LlI 
of DMSO and 1000 )11 distilled water. 
The absorbance was read on a Varian Cary 100 Conc UV spectrometer at 402 nm. 
A stable reading was taken for the analyte before adding between twenty six and 
thirty three increments of increasing volume of the drug stock solution and taking a 
stable reading after each increment. 
Instruments that were used include Crison micropH 2000 pH-meter to determine pH 
for which standard buffer solutions were used at pH 4.00 :: 0.02 and 7.00 ± 0.02, to 
calibrate the meter before use. Eppendorf Research micropipettes were used to 
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The data points were then analyzed using a non-linear least squares fitting program. 
Each titration was performed in triplicate. 
5.2.4. Antiplasmodial activity 
All compounds 11,12,13,14,15 and 16 were tested for antiplasmodial activity against 
the chloroquine sensitive 010 strain and the chloroquine resistant K1 strain of P. 
falciparum. Testing was done by Mr. Donnelly van Schalkwyk at the department of 
Pharmacology, University of Cape Town. The parasites were cultured continuously 
by the method of Trager and Jensen.[105] The compounds were dissolved either in 
methanol or ethanol and the diluted with medium to final concentrations which 
contained less than 1 % methanol/ethanol which were found to be non toxic to the 
parasites. Chloroquine diphosphate was dissolved in water. Parasite lactate 
dehydrogenase was measured to assess antiplasmodial activity. This was done by a 
modified method of Makler et a/.l106] The anti plasmodial testing was performed at 1 % 
hematocrit and 2% paraSitemia. Compounds were added at a late trophozoite stage 
and parasites cultured in their presence for a period of 48 Hours before lactate 
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